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1. Introduction 
 
1.1. c-Myc transcription factor 
The c-myc proto-oncogene is the cellular homologue of v-myc, the transforming gene 
of the MC29 avian leukaemia virus (Sheiness et al., 1978).  Deregulated c-myc 
expression has been demonstrated in many types of human cancers, including 
Burkitt's lymphoma, myeloid and plasma cell leukaemia, breast carcinoma, cervical 
carcinoma, small cell lung carcinoma, colon carcinoma, osteosarcoma, and 
glioblastoma (Spencer and Groudine, 1991; DePinho et al., 1991).  Myc family genes 
(comprising C-, N-, and L-Myc) code for proteins that promote proliferation, growth, 
and apoptosis, inhibit terminal differentiation and, when deregulated, are greatly 
involved in the genesis of an extraordinarily wide range of cancers (Grandori et al. 
2000). 
1.2. c-Myc protein 
The gene product encoded by the c-myc proto-oncogene is a transcription factor 
whose carboxy terminus contains three structural domains homologous to domains 
found in other transcription factors, including a leucine zipper (Zip), a helix-loop-helix 
motif (HLH), and an adjacent domain rich in basic amino acids (b) (Fig 1) (Blackwell 
et al., 1990; Landshulz et al., 1988; Murre et al., 1989). 
The HLH and Zip motifs mediate protein-protein interaction, and the basic region 
mediates sequence-specific DNA binding (Blackwell et al., 1990; Landshulz et al., 
1988; Murre et al., 1989).  The c-Myc amino terminus (aa 1-143) comprises the TAD 
region, which is required for transcriptional activation and is conserved in all Myc 
family members.  The TAD region includes Myc box I (MBI), which has two important 
phosphorylation sites (Thr58 and Ser62), associated with activation and protein 
degradation (Stone et al., 1987; Sears et al., 2004), Myc box II (MBII), needed for 
interaction with the transformation/transcription domain-associated protein (TRRAP) 
transcriptional coactivator and critical for most Myc biological functions (Oster et al., 
2002; Pelengaris et al., 2002; Freytag et al., 1990), Myc box III (MBIII), involved in 
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transcriptional repression (Kurland and Tansey, 2008; Herbst et al., 2005) and Myc 
box IV (MBIV), which contains one of the c-Myc nuclear localisation signals (NLS) 
and is implicated in modulating  DNA binding (Cowling et al., 2006). 
 
1.3. c-Myc regulation 
Expression of the c-myc gene is under intense regulation at both transcriptional and 
post-transcriptional levels.  c-Myc mRNA has an approximately 20-30 min half-life, 
related to A- and U-rich sequences in the 3' UTR region (Jones and Cole, 1987; 
Brewer and Ross, 1988). c-Myc protein bears one of the hallmarks of regulatory 
proteins; it is an extremely short-lived phosphoproteins that is localised 
predominantly in the cell nucleus. 
c-Myc levels are precisely regulated throughout cell life.  c-Myc protein is 
undetectable in quiescent cells, but after exposure to many types of mitogens, its 
expression is rapidly upregulated and promotes G0/G1 to S phase transition (Kelly et 
al., 1983; Campisi et al., 1984).  The ubiquitin/26S proteasome pathway controls 
Fig 1. Structure of Myc/Max/Mad network proteins. Functional domains of c-  
and different bHLHZ transcription factors 
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regulation of c-Myc protein, which has at least 10 phosphorylation sites (Henriksson 
et al., 1993).  c-Myc phosphorylation has an important role in regulation of its 
proteolysis, just as in the biological functions.  Two main phosphorylation sites, Ser62 
and Thr58, are responsible for c-Myc stabilisation and degradation.  Whereas 
phosphorylation at Ser62 stabilises c-Myc protein, phosphorylation at Thr58 leads to 
its degradation (Hann et al., 2006). In many lymphomas, point mutations at c-Myc 
Ser62 and Thr58 appear to be linked to Myc transformation activity (Nasi et al., 
2001). 
1.4. The c-Myc network 
The bHLHZ domain of Myc, located at its carboxy terminus, mediates 
heterodimerisation with the bHLHZ protein Max, to produce a heterocomplex with 
specific DNA-binding activity (Blackwoodand and Eisenman, 1991; Ayer and 
Eisenman, 1993; Amati and Land, 1994) (Fig 1). 
1.4.1. Max  
Max is a small, ubiquitously expressed protein that binds to many bHLHZip proteins 
(Baudino and Cleveland, 2001).  Since the Max protein lacks a TAD domain, Myc is 
responsible for activating transcription of the target genes (Vervoorts and Larsson, 
1999).  Myc-Max heterodimers recognise the consensus enhancer box (E-box)-
related sequence CACGTG with high affinity, and also bind to a group of other E-box- 
and non-E-box-related sequences with lower affinity.  E-box-bound Myc-Max 
interacts with the basal transcription apparatus and with complexes that remodel and 
modify chromatin.  Myc-Max heterodimers induce relatively modest activation of 
transcription (from three- to ten-fold) when the binding site(s) is placed proximal to a 
minimal TATA-box-containing promoter. 
1.4.2. Mad, Mnt and Mxi 
Max interacts with several distinct classes of bHLHZ proteins, including the Mad 
protein family and three recently-described proteins, Mnt, Mxi and Mga.  When bound 
to Max, Mad family members bind E-box sequences and compete for binding with 
c-Myc/Max heterodimers.  Mad-Max, Mnt-Max and Mxi-Max complexes function as 
transcriptional repressors at E-box-containing promoters and are thought to 
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antagonise Myc-Max functions (Ayer and Eisenman, 1993; Ayer et al., 1993; Zervos 
et al., 1993; Amati, 2001). 
Mad-Max, Mnt-Max, and Mxi-Max complexes mediate transcriptional repression of 
their target genes through their alpha-helical amino-terminal domain (SID) (Fig 1).  
This domain is needed for interaction with the transcriptional corepressors Sin3a and 
Sin3b and with a multisubunit complex that includes the transcriptional corepressors 
N-CoR, the histones HDAC1 and 2, and the oncoproteins Ski and Sno, all of which 
alter chromatin structure and block transcription through deacetylation of histone tails 
(Alland et al., 1997; Hassig et al., 1997; Laherty et al., 1997, Shinagawa et al., 2000) 
(Fig 2).  In contrast to Max, which is ubiquitously expressed, the Mad-Mnt proteins 
are induced during terminal differentiation of many cell types. 
 
Another c-Myc-mediated mechanism of trans-repression involves binding to the 
transcriptional activator Miz-1, which interferes with c-Myc transactivation ability and 
causes trans-repression of specific Miz-1 target genes (Staller et al., 2001; Wu et al., 
2003; Wanzel et al., 2003).  One study demonstrated that c-Myc is recruited to the 
p21 promoter by Miz1.  This interaction prevents p21 induction by p53, resulting in 
the initiation of apoptosis rather than cell cycle arrest (Wu, 2003; Herold et al., 2002; 
Fig 2. Mechanisms of transcriptional activation and repression by c-Myc 
network 	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Seoane et al., 2002).  c-Myc acts as a molecular bridge between Miz-1 bound to the 
p21 promoter and the DNA methylase Dnmt3a to mediate methylation and 
transcriptional silencing of p21 (Brenner et al., 2005).  Another possible mechanism 
of trans-repression might involve c-Myc interaction with CAAT box-binding proteins 
such as NF-Y.  This appears to be the case with the transcriptional repression of 
PDGFR-β and perhaps of collagen genes (Hackzell et al., 2002).  c-Myc was also 
shown to repress the proximal promoters of GADD45a and GADD153 by a post-RNA 
polymerase II recruitment mechanism (Barsyte-Lovejoy et al., 2004). 
Mga has a T domain near its amino terminus, which is a conserved DNA and protein-
binding motif found in the Brachyury family of cell specification transcription factors 
(Hurlin et al., 1999). It normally represses promoters harbouring T boxes, but 
activates transcription from E-box when it interacts with Max, switching from a 
repressor to an activator (Fig 4). 
These studies provide evidence that c-Myc can inhibit transcription by directly 
interfering with other factors that activate gene expression. 
1.5. Transcriptional activation 
Normally DNA is tightly wound around the histones, and chromatin remodelling is 
necessary to allow transcription factor access to the regulatory regions of genes.  
Two mechanisms of chromatin remodelling have been described thus far for c-Myc 
protein: ATP-dependent remodelling and histone acetylation (Fig 2).  During the ATP-
dependent chromatin remodelling process, c-Myc interacts with INI1/hSNF5 (Cheng 
et al., 1999), a component of the SWI-SNF complex that remodels chromatin in an 
ATP-dependent manner.  This reorganisation induces nucleosomes to move along 
the DNA, enabling access to transcription machinery (Whitehouse et al., 1999).  In 
the case of histone acetylation, c-Myc recruits a coactivator complex containing 
TRRAP and histone acetyl transferases (HAT) such as GNC5 (McMahon et al., 1998; 
McMahon et al., 2000) and TIP60 (Campbell et al., 2003), which acetylate H4 and H3 
histones, respectively.  Acetylation opens up the chromatin structure, allowing 
enhanced transcription of c-Myc target genes. 
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1.6. Transcriptional repressor 
In addition to its function as a transcriptional activator, which has been broadly 
studied, c-Myc also acts as a transcriptional repressor.  Several genes have been 
identified as targets for transcriptional repression by Myc, and it is not surprising that 
many of these genes have roles in cell cycle or growth regulation. 
Although most target genes repressed by c-Myc are TATA-less promoters and 
contain initiator elements (Inr) within the promoter regions, c-Myc is able to mediate 
repression of genes that lack Inr elements (Gartel and Shchors, 2003).  In the case of 
Inr-dependent repression, c-Myc interacts with Inr-binding transcriptional activators 
such as TFII-I, YY1 and Miz-1, and forms a DNA-associated complex containing an 
Inr sequence, leading to inhibition of target gene activation (Henriksson and Luscher, 
1996) (Fig. 3).  This complex resists further binding of basal transcriptional 
machinery, and thus prevents transcriptional activation by the Inr (Roy et al., 1993b).  
A Myc-Max complex binds to the Inr element of the p27 promoter (Yang W et al., 
2001). A conserved element in the MBIII region is important for transcriptional 
Fig 3. Transcriptional repression mediated by c-Myc through Inr motif 
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repression of target genes such as Id2 and Gadd153, through recruitment of the 
HDAC3 histone deacetylases to both gene promoters (Kurland and Tansey, 2008). 
In an Inr-independent mechanism, c-Myc binds the transcription factors Sp1 and Sp3 
via its central motif, thereby inhibiting their transcriptional activity (Gartel and 
Shchors, 2003) (Fig. 3).  Genes repressed in this way are gadd45 (Marhin et 
al.,1997),	  p15 (Feng et al., 2002) and p21 (Gartel et al., 2001)(Fig 4). 
1.7. c-Myc biological functions 
c-Myc influences a variety of cell functions, including cell cycle regulation, 
metabolism, apoptosis, differentiation and adhesion, and deregulated expression 
participates in tumorigenesis. 
Fig 4. Inr-independent mechanisms of repression by c-Myc (a) and Mga (b). 
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1.7.1. Cell cycle  
c-Myc expression is elevated during embryogenesis and in rapidly proliferating adult 
tissues, such as epithelial and progenitor cells.  c-Myc levels are regulated 
throughout the cell cycle.  Quiescent cells in vitro express almost undetectable levels 
of c-Myc, but after mitogen or serum stimulation, c-Myc levels are induced and cells 
enter the G1 phase.  Deregulated expression of c-myc characterises oncogenic 
activation and is a frequent hallmark of tumour-derived cells (Adams and Cory, 1985; 
Dalla-Favera et al., 1982; Morgenbesser and DePinho, 1994).  Many studies have 
shown that c-Myc regulates the cell cycle through its ability to activate or repress the 
expression of genes involved in cell cycle progression. 
c-Myc regulates the G1/S transition, and c-Myc expression is reportedly sufficient to 
overcome the checkpoint and to induce S phase entry in the absence of growth 
factors (Eilers, 1999).  In addition, studies in both Rat1a and c-myc -/- mouse 
embryonic fibroblasts (MEF) showed that these cells have prolonged doubling times 
and G1  and G2 phases (de Alborán  et al., 2001; Mateyak et al., 1997). 
Cell cycle progression is promoted by cyclin-dependent kinases (CDK) and their 
cyclin regulatory subunits.  Deregulated c-Myc expression leads to direct or indirect 
activation of the cyclin D1, D2, E and A genes (Bouchard et al., 1999; Daksis, 1994; 
Hoang et al., 1994), as well as cdk4 (Hermeking et al., 2000) and Cdc25A 
(Galaktionov et al., 1996), a phosphatase that activates CDK2 and CDK4.  c-Myc 
also suppresses cyclin kinase inhibitors such as p15ink4b , p21cip1 and p27kip1 (Dang, 
1999; Grandori et al., 2000). 
The activity of both CDK2 and CDK4 result in retinoblastoma protein (Rb) 
hyperphosphorylation and release of E2F from Rb, which regulates genes implicated 
in replication and mitosis (Humbert et al., 2000; Ishida et al., 2001; Muller et al., 
2001). 
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1.7.2. Apoptosis 
c-Myc has an important role in apoptosis.  Ectopic c-Myc expression in serum-
starved fibroblasts leads to apoptosis and loss of the entire population (Evan et al., 
1992); indeed, subsequent studies showed the involvement of many c-Myc target 
genes in the process of apoptosis (Morrish et al., 2003).  c-Myc induces apoptosis by 
at least four different mechanisms.  In the first case, it induces activation of BAX, a 
pro-apoptotic molecule that also induces cytochrome c release from mitochondria 
(Soucie et al., 2001). In a second mechanism, it induces cytochrome c release from 
mitochondria, which in turn associate with APAF1 protein, activating pro-caspase 9 
and promoting the downstream caspase cascade, leading to apoptosis (Juin et al., 
1999).  A third pathway is enhancement of cell sensitivity to signalling through the 
CD95 death receptor, which triggers association of the intracellular adaptor protein 
FADD with the CD95 receptor, recruiting pro-capase 8 and leading to activation of the 
caspase cascade (Hueber et al., 1997).  Finally, c-Myc induces apoptosis by indirect 
activation of p53 via ARF, which activates the p19/Mdm2/p53 apoptotic pathway 
(Zindy et al., 1998). 
1.7.3. Cell growth 
All organisms must coordinate their increase in cell size with division (Neufeld and 
Edgar, 1998).  Although the mechanism by which c-Myc regulates cell growth is not 
yet well understood, there are some candidate target genes that regulate protein 
synthesis as well as cell metabolism, such as eIF2a, eIF4E, RNA helicase MrDb, 
IRP-2 and H-ferritin  (Grandori et al., 2000).  c-Myc overexpression in flies causes 
tissue growth by increasing cell size (Johnston et al., 1999) and in mammals also 
produces larger cells (i.e., in B lymphocytes of Em-myc transgenic mice at different 
stages) (Irritani and Eisenman, 1999).  After BCR- or mitogen-induced activation, 
primary B lymphocytes progress from small quiescent B cells to large B cell blasts 
(Thompson et al., 1984). Following treatment with anti-CD40 plus interleukin 4 
(interleukin-4), however, c-Myc-deficient B lymphocytes are unable to increase in size 
(de Alborán et al., 2001).  Ectopic expression of c-myc in liver promotes enlargement 
of hepatocytes in the absence of proliferation or apoptosis (Kim et al., 2000), 
whereas c-myc inactivation in liver causes a decrease in hepatocyte size, as well as 
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smaller cell area (Baena et al., 2005). 
Recent studies show that c-Myc regulates the expression of genes transcribed by 
RNA polymerase III (such as tRNA and 5S rRNA) and RNA polymerase I (genes 
encoding ribosomal RNA) (Dai et al., 2010). 
1.7.4. B lymphocyte differentiation 
In addition to its functions in cell proliferation, apoptosis and cell growth, c-Myc plays 
an important role in cell differentiation.  c-Myc is normally expressed in immature 
proliferating cells and its downregulation is reported to trigger cell differentiation 
(Chang et al., 2000; Henriksson and Luscher, 1996. Ectopic c-myc expression blocks 
terminal differentiation in many cell types, both in vivo and in vitro (Facchin and 
Facchin, 1998; Iritani and Eisenman, 1999). In B lymphocytes, Blimp-1 
overexpression in a pro-monocytic cell line triggers transcriptional repression of 
c-myc, which induces differentiation to macrophages and B cells (Chang et al., 2000). 
Overexpression of c-myc in Eµ-c-myc mice leads to accumulation of immature pre-B 
cells in the bone marrow of these animals (Iritani and Eiseman, 1999). 
B cell development is a highly regulated process whereby functional peripheral 
subsets are produced from haematopoietic stem cells, in the foetal liver before birth 
and in the bone marrow afterward (Osmond and Everett, 1964); it further proceeds in 
secondary lymphoid organs (such as spleen, Peyerʼs patches and lymph nodes).  
B cells differentiate from haematopoietic precursors and then undergo receptor 
rearrangement, resulting in the establishment of a diverse repertoire of 
B lymphocytes able to meet most of the antigenic challenges encountered in life. 
Receptor diversification is a stochastic process that is largely antigen-independent, 
although signals delivered through the antigen receptor play an important part in 
regulating lymphocyte development.  During B cell development, several key events 
take place.  First, the B cell population expands from a small number of precursors 
into a very large population of immature B cells, which emigrate to the periphery to 
compete for entry in the recirculating repertoire of naïve mature B cells (Hardy and 
Hayakawa, 2001).  Second, within each developing B cell, genes encoding the 
variable regions of immunoglobulin heavy-chain (IgH) and light-chain (IgL) molecules 
undergo rearrangement to diversify the repertoire of available receptors, resulting in 
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an estimated 1011 specificities (Davis and Bjorkman, 1988). 
Third, the B cell repertoire is modified to eliminate or silence those lymphocytes that 
express antigen receptors (surface Ig) that bind self-antigen with high affinity.  This 
developmental pathway has been thoroughly studied and characterised in the past 
years, revealing important growth factors and regulatory interactions and identifying 
different developmental stages based on cell surface expression proteins, which has 
given rise to many nomenclatures (Fig 5). 
 
B lineage cells account for approximately 30% of nucleated cells in adult mouse bone 
marrow (Picker and Siegelman, 1999).  Haematopoietic stem cells (HSC) differentiate 
to common lymphoid progenitors (CLP), which are B200+, IL7Ra+, c-Kitlow and 
ScaIlow.  These CLP represent about 0.03% of bone marrow cells, and can give rise 
to B, T and natural killer cells (Kondo et al., 1997).  B lineage-restricted cells, starting 
from pre-pro-B cells (Fig 5, fraction A), are characterised by expression of B220 and  
CD43 markers and the beginning of DH-JH rearrangement.  These cells give rise to  
 
 
pro-B cells (fraction B/C), and are characterised by expression of the CD19 surface 
marker and the onset of VH-to-DJH rearrangement.  IgH rearrangements follow an 
orchestrated sequence.  Once productive DH-JH joining is complete, VH-DJH 
	  
Fig 5. B cell development. B cell nomenclatures and expression markers. 	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rearrangement begins.  Productive VH-DJH joining leads to expression of the m chain, 
giving rise to the pre-B cell stage, which comprises later phases (fractions C and D).  
The pre-B cell receptor is formed by pairing µ chain with the surrogate light chain 
molecules (l5 and VpreB) and the signalling molecules Igα and Igβ. 
Pre-BCR expression on the surface of pre-B cells results in their increased 
proliferation before giving rise to the next fraction.  Once a light chain gene is 
assembled and complete IgM receptor is expressed on the cell surface, cells are 
called immature B cells (fraction E).  This process takes places in bone marrow and 
is antigen-independent, after which immature B cells move to the periphery where 
they are subject to selection for self-tolerance.  Surviving cells undergo further 
differentiation to become mature B cells, characterised by IgM and IgD expression on 
the cell surface (naïve B cells); they recirculate through secondary lymphoid organs 
until they encounter their specific antigen and are activated, giving rise to plasma 
cells. 
1.8. Transcriptional control of early B lymphocyte development 
The development of mature B lymphocytes from multipotent progenitors requires the 
coordinated action of a number of transcription factors, such as Ikaros, PU.1, E2a, 
early B cell factor (Ebf1) and B cell-specific activator protein (BSAP/Pax-5).  Whereas 
Ikaros (Georgopoulos et al., 1994) and Pu.1 (Scott et al., 1994) act in the 
development of multipotent progenitors, E2a (Zhuang et al., 1994), Ebf1 (Lin et al., 
1995), and Pax-5 (Urbanek et al., 1994) are specifically needed for development at 
the time of or after commitment to the B lineage. 
Several key B cell lineage genes, including rag1, tdt, l5 and vpreb are regulated by 
Ikaros.  This commitment to B lineage differentiation is signalled by initiation of 
rearrangement of the variable (V), diversity (D) and joining (J) segments of DNA that 
encode the IgH genes, and by intranuclear expression of terminal deoxynucleotide 
transferase (TdT), which inserts nontemplated nucleotides at VH segment joints and 
requires expression of the transcription factors e2a, ebf1, pax5 and low levels of 
pu.1.  Expression of e2a and ebf1 leads to upregulation of Iga/b, vpreb, l5 and rag1/2, 
which together with pax5 are essential for B cell identity. 
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1.8.1. Ikaros 
The Ikaros proteins are a family of conserved zinc-finger DNA-binding transcription 
factors characterised by a highly conserved C2H2 zinc finger DNA-binding domain 
near the N terminus and a C2H2 zinc finger protein-protein interaction domain near 
the C terminus that mediates the formation of dimers and multimers between Ikaros 
family members (Georgopoulos et al., 1992; Hahm et al., 1994).  Ikaros is expressed 
during embryogenesis only at sites of haematopoiesis, and in the adult in early B 
cells, T cell progenitors and mature T cells.  High-affinity binding sites for Ikaros have 
been identified in the regulatory regions of many lymphocyte-specific genes (Molnar 
and Georgopoulos, 1994). 
The Ikaros gene, encoding a zinc-finger transcription factor, exerts a critical role 
during very early stages of B cell development. In mouse and humans, the Ikaros 
family has five members. Pegasus and Eos are broadly expressed, whereas Ikaros, 
Aiolos, and Helios are restricted to hematopoietic cells. Ikaros protein has been 
shown to bind to regulatory elements present in the promoter regions of tdt and l5 of 
B cells (Sabbattini et al., 2001). 
1.8.2. E2a 
E2a has two splice variants, E12 and E47, and is encoded by the tcfe2a gene. It 
belongs to bHLH family of transcription factors (Kadesch, 1992) and is expressed 
predominantly in B lineage cells.  e2a-deficient mice show a developmental block at 
the pre-pro-B cell stage (Bain et al., 1994) and are unable to rearrange DH to JH 
segments due to the absence of rag1 expression (Bain et al., 1994; Borghesi et al., 
2005).  e2a knockout progenitors show normal levels of IL-7Ra, Igb and Igm0, but 
decreased ebf1 levels and no pax5, cd19, Iga or l5 expression (Bain et al., 1994; 
Bain et al., 1997). 
The ebf1 promoter contains E2a binding sites, and E2a activates ebf1 expression 
(Roessler et al., 2007; Smith et al., 2002).  Forced expression of ebf1 in e2a-deficient 
HSC promotes development of pro-B cells in vitro (Bain et al., 1994; Seet et al., 
2004), but these cells are unable to proliferate due to the lack of the E2a-IL-7R 
pathway that upregulates N-myc expression (Seet et al., 2004). 
Studies in conditional e2a knockout mice showed that E2a is necessary for the 
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generation and development of pro-B, pre-B and immature B cells in bone marrow 
and for development of germinal centre B cells in the spleen, but is dispensable for 
generation of mature and plasma B cells in peripheral organs (Kwon et al., 2008).  
Gene expression analysis of these e2a conditional knockout pro-B cells indicated that 
ebf1, pax5, cd19, cd79a, cd79b and Igll1 levels are downregulated compared to 
those of WT pro-B cells.  E2a therefore controls expression of ebf1, acts upstream of 
pax5, and is needed for maintenance of the gene expression programme of pro-B 
cells. 
1.8.3. Ebf1 
Early B cell factor 1 (Ebf1) is a member of the COE (Collier Olf EBF) family of 
transcription factors that bind DNA through a zinc motif in the N-terminal domain 
(Hagman et al., 1993; Hagman and Lukin, 2005); it contains a C-terminal domain 
related to the HLH domain and mediates Ebf1 homodimer formation.  Ebf1 is 
expressed in brain, adipose tissue, olfactory neurons (Wang and Reed, 1993) and in 
all B cell stages except plasma cells, where its expression is downregulated 
(Hagman and Lukin, 2005). This protein can bind DNA as a monomer or homodimer 
on correctly spaced DNA half-sites. 
Expression of the ebf1 gene involves two promoters that are differentially regulated 
and gives rise to two isoforms, Ebf1β and Ebf1β, which differ in the first 14 amino 
acids but have the same transactivation potential (Roessler et al., 2007).  One distal 
promoter, termed ebf1α promoter, is activated by E2a, the IL-7 pathway and by Ebf1 
itself in a feedback loop (Smith, 2002), and a proximal promoter, termed ebf1β 
promoter, is controlled by Pax5 and ETS1 proteins. ebf1 expression is therefore 
tightly controlled by a well-regulated mechanism in which E2a activates ebf1 
expression by binding the ebf1α promoter, and Ebf1α binds and activates the Pax5 
promoter; this in turn binds the ebf1β promoter and regulates ebf1β expression in a 
feedback loop. 
Several studies have shown a role for Ebf1 in the B cell specification program.  For 
example, retroviral expression of ebf1 in HSC promotes B cell differentiation (Zhang 
et al., 2003).  Ectopic ebf1 expression rescues B cell development in e2a-deficient 
HSC (Bain et al., 1994; Seet et al., 2004), in pu.1 knockout HSC (Medina et al., 2004) 
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and in IL-7R-deficient pre-pro-B cells and CLP (Dias et al., 2005; Kikuchi et al., 
2005).  In all these cases, pax5 expression does not rescue B lymphocyte 
development, indicating that Ebf1 might have other activities in addition to activation 
of the pax5 gene. 
Forced ebf1 expression in e2a or pu.1-deficient progenitors results in the activation of 
pax5 gene expression (Akerblad et al., 1999; Medina et al., 2004).  Overexpression 
of ebf1 and e2a in Ba/F3 cells nonetheless does not induce pax5, suggesting that 
pax5 activation by ebf1 might require additional transcription factors expressed in 
lymphoid progenitor cells, but not in Ba/F3 cells (Roessler et al., 2007). 
1.8.4. Pax5 
Pax5 is one of nine mammalian Pax transcription factors, yet it is the only Pax protein 
expressed in the haematopoietic system.  The pax5 gene encoding the B cell-specific 
activator protein (BSAP or Pax5) is the master regulator of B cell commitment.  Pax5 
was first identified as a DNA-binding factor that interacts with segments of the 
immunoglobulin heavy-chain (Igh) and klight-chain (Igk) gene loci (Adams et al., 
1992).  Pax5 was discovered independently as a DNA-binding protein with the same 
DNA sequence specificity as the sea urchin transcription factor TSAP (Barberis et al., 
1989).  Biochemical purification and cDNA cloning showed that BSAP is encoded by 
the Pax5 gene. 
pax5-/- pro-B cells can completely restore thymocyte development in RAG2-deficient 
mice (Rolink et al., 1999) and differentiate efficiently in vitro into T cells during culture 
with OP9 stromal cells expressing the Notch ligand Delta-like 1 (DL1).  pax5-/- pro-B 
cells are unable to differentiate into mature B cells, however, unless their B cell 
potential is rescued by retroviral restoration of Pax5 expression (Nutt et al., 1999).  
Pax5 is therefore considered the critical B cell lineage commitment factor that 
restricts the developmental options of lymphoid progenitors to the B cell pathway. 
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1.9. Terminal B cell differentiation 
The principal function of B cells is to produce antibodies against antigens.  Antibody 
production involves three different processes: VDJ recombination, Somatic 
Hypermutation (SHM) and Class Switch Recombination (CSR).  VDJ recombination 
takes place in the bone marrow, where immunoglobulin variable regions from heavy 
and light chains of Ig genes are rearranged to produce a primary repertoire of IgM 
antibodies with low affinity binding for antigen. 
Once naïve mature B cells encounter an antigen, they present it through major 
histocompatibility complex (MHC) class II to CD4+ T cells (T-helper cells). This 
contact causes activation of the B cells, which proliferate and migrate into the dark 
zone of the germinal centre (GC) in peripheral lymphoid organs such as spleen, 
lymph node, tonsil and Peyerʼs patches, where they become centroblasts. 
This differentiation to centroblasts is associated with expression of activation-induced 
cytidine deaminase (AID), which alters the Ig genes by triggering SHM and CSR 
(Fig 7).  When these processes are complete, those cells that have acquired higher 
affinity for antigen due to successful SHM are positively selected to differentiate into 
plasma or memory B cells, in which CSR has modified the antibody isotype, and to 
migrate to the light zone of the GC.  Those B cells that have not undergone affinity 
maturation or have become autoreactive either undergo apoptosis or become anergic 
(MacLennan 1994). 
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1.9.1. Class switch recombination 
CSR alters the isotype of antibody produced by a B cell from IgM or IgD to IgG, IgE or 
IgA, adding diverse effector functions while preserving antigen specificity.  The heavy 
chain constant region (CH) in mouse has eight genes, organized as Cβ Cδ, Cγ3, Cγ1, 
Cγ2b, Cγ2a, Cε and Cα (Fig 6). 
CSR takes places between large repetitive switch regions located upstream of each 
CH region gene, except for Cδ, with the excision and loss of all intervening sequences 
(Stavnezer et al., 2000).  Once CSR occurs, the prior Cm constant region expressed 
during development is replaced with one of the downstream CH exons (Cγ3, Cγ1, 
Cγ2β, Cγ2α, Cε or Cα).  This region confers different properties on the antibody, such 
as the ability to bind complement, to bind to Fc receptors, to polymerize, to increase 
avidity, to diffuse into tissues or to remain in the circulation. 
To carry out the CSR process, transcription is necessary through each of the CH 
regions in which recombination has to take place.  This transcription produces a 
sterile or germline transcript (GLT) that is spliced, but does not encode a protein 
(Fig 6). This GLT remains stably associated with the DNA template strand and forms  
 
 
 
 
 
 
 
 
 
 
Fig 6. AID regulates CSR. The CH region exons are switched from	   Cµ to one of the 
downstream C genes. This process depends on transcription of the target gene segment 
(Germline transcript-GLT) and the expression of AID, both of which are induced by 
cytokines and others stimuli. Upstream of the I exon is a promoter responsive to specific 
cytokine. The recombination target is determined by the activation of the specific germline 
promoter. 
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RNA-DNA hybrids, allowing formation of many loops in the non-template, single-
stranded DNA due to the presence of G-rich sequences (R loop structure) (Shinkura 
et al., 2003; Yu et al., 2003).  Each of the promoters of the S regions is differentially 
transcribed in response to different mitogens and cytokines; this mechanism directs 
the class switch to specific isotypes (reviewed in Stavnezer, 2000) (Fig 6). 
Lipopolysaccharide (LPS) induces expression of GLT and class switching to γ2b and 
γ3, whereas anti-CD40 plus interleukin-4 induces switching to γ1 and ε (reviewed in 
Coffman et al., 1993).  In addition, the presence of enhancers located at the 3ʼ end of 
the heavy chain locus appear to regulate the CSR, since deletion of some causes 
loss of switching to certain isotypes (Pinaud et al., 2001). 
1.9.2. Activation-induced cytidine deaminase (AID) 
In addition to GLT expression, B cells must express AID protein to carry out the CSR 
process.  AID was originally described as a B cell-specific factor unique to activated 
germinal centre B cells.  In this setting, AID expression is induced by signals that 
induce CSR in naïve B cells, such as exposure to pathogenic stimuli, T cell help, and 
specific cytokines. AID initiates CSR by introducing G:U mismatches into the Sm and 
recipient S switch regions (Fig 7) by deaminating cytidine residues in single-stranded 
DNA (Bransteitter et al., 2003; Chaudhuri et al., 2003; Dickerson et al., 2003; Pham 
et al., 2003; Ramiro et al., 2003; Sohail et al., 2003).  The resulting G:U mismatches 
are processed by several different DNA repair mechanisms to produce mutations or 
DNA double-strand breaks (Di Noia and Neuberger, 2007; Peled et al., 2008), which 
after a regulated process, give rise to CSR.  AID also contributes to malignant 
transformation by initiating chromosome translocations (Ramiro et al., 2004, 2006; 
Robbiani et al., 2008; Jankovic et al., 2010).  AID is a 198-amino-acid enzyme 
(Muramatsu et al., 1999) that deaminates cytosine residues embedded in WRCY 
consensus sequences (where W = adenosine/thymine, R = purine, and Y = 
pyrimidine) (Rogozin and Kolchanov, 1992).  This preference is dictated in part by the 
composition of the active site (Wang et al., 2010), although it cannot fully account for 
AID target choice.  While several AID cofactors have been reported, including 
replication protein A (RPA), protein kinase-Ar1a, and CTNNBL1, none of these are 
known to impart specificity to AID (Basu et al., 2005; Chaudhuri et al., 2004; 
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Conticello et al., 2008; McBride et al., 2006; Pasqualucci et al., 2006). 
1.9.3. Class switch recombination and cell division 
There is a well-documented relationship between cell division and CSR, both in human 
and in murine B cells, showing evidence of a division-linked increase in the frequency 
of cell surface expression of switched Ig isotypes after stimulation (Tangye and 
Hodgkin PD., 2004). Division-linked CSR operates at both the molecular and cellular 
levels, increasing the number of switched cells with successive divisions in a time-
independent manner (Rush et al., 2005).  Undivided cells are unable to switch even 
after 4 days of in vitro stimulation; this is due to low AID mRNA expression, as well as 
to low GLT and H3 acetylation levels indicating that the switch regions are not fully 
accessible in undivided cells.  It is also necessary that single-strand lesions generated 
by the combined action of AID and the mismatch repair (MMR) and base-excision 
repair (BER) pathways are converted into double-strand breaks by replication of the 
IgH locus during S phase.  In addition, certain DNA repair pathways involved in CSR 
operate in specific cell cycle stages, which might prevent recombination until the cell 
enters and completes these stages. It was therefore proposed that at least one round 
of DNA replication is required for CSR (Rush et al., 2005; Lundgren et al., 1995). 
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2. Aims 
 
 
 
 
 
2.1. To define c-Myc target genes involved in early B cell differentiation using 
conditional mouse models. 
 
 
 
 
 
2.2. To characterize the role of c-Myc in heavy chain class switch 
recombination. 	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3.1. Mice 
To generate c-mycfl/fl;mb-1cre/+ mice, c-mycfl/fl were bred with mb-1cre/+ mice (Hobeika 
et al., 2006) and progeny crossbred to yield homozygous (c-mycfl/fl;mb-1cre/+) and 
control mice (c-mycfl/+;mb-1cre/+).  nMice were genotyped using a PCR-based analysis 
of tail genomic DNA (de Alborán et al., 2004; Baena et al., 2005).  The primers hcre-
DIR (5'-ACCTCTGATGAAGTCAGGAAGAAC-3'), hcre-REV (5'-GGAGATGTCCTTC 
ACTCTGATTCT-3'), mb-1in1 (5'-CTGCGGGTAGAAGGGGGTC-3') and mb-1in2 (5'-
CCTTGCGAGGTCAGGGAGCC-3') were used to amplify mb-1-cre (hcre-DIR and 
hcre-REV) and mb-1-wt alleles (mb-1in1 and mb-1in2). 
The rosa26-egfp allele was genotyped as described (Mao et al., 2001). To generate 
c-mycfl/fl cd19cre/+ mice first we bred c-mycfl/fl with cd19cre/+ (Rickert et al., 1997) and 
progeny bred to yield homozygous (c-mycfl/flcd19cre/+) nd control mice 
(c-mycfl/+cd19cre/+).  Briefly, c-mycfl/flcd19cre/+ were bred with rosa26egfp/egfp mice (Mao 
et al., 2001) and progeny crossbred to yield homozygous 
c-mycfl/flcd19cre/+rosa26egfp/egfp or heterozygous c-mycfl/+cd19cre/+rosa26egfp/egfp mice.  
To generate c-mycfl/flcd19cre/+rosa26egfp/egfp IgK-AID, we crossed 
c-mycfl/flcd19cre/+rosa26egfp/egfp with Igk-AID transgenic mouse (Robbiani et al,. 2009). 
 
Mice were genotyped using a PCR-based analysis of tail genomic DNA (de Alborán 
et al., 2004; Baena et al., 2005).  To amplify the different alleles, we used the 
following primer pairs: floxed c-myc allele, Flox S (5ʼ-GCCCCTGAATTGCTAGGAAG 
ACTG-3ʼ) and Flox A (5ʼ-CCGACCGGGTCCGAGTCCCTATT-3ʼ) (530 bp product). 
cd19-cre allele, Cre 3 (5ʼ-CAATTTACTGACCGTACA-3ʼ) and Cre 4 (5ʼ-CATCGCCAT 
CTTCCAGCA-3ʼ) (1000 bp product).  Cd19 wt allele, Cd19.8 (5ʼ-AATGTTGTGCTGC 
CATGCCTC-3ʼ) and Cd19.9 (5ʼ-GTCTGAAGCATTCCACCGGAA-3ʼ) (550 bp 
product).  Rosa26-egfp allele, lac-Z1 (5ʼ-GTGGTGGTTATGCCGATCG-3ʼ) and lac-Z2 
(5ʼ-TACCACAGCGGATGGTTCGG-3ʼ).  For the AID tg allele, oIMR7486 (5ʼ- GTGGC 
TGAGTTTCTGAGATGGAAC-3ʼ) and oIMR7487 (5ʼ- AACAGTGGTAGGTCGCTT 
GTGG-3ʼ) (434 bp product).  aicda KO mice were crossbred to yield homozygous 
knockout mice and were genotyped as described (Muramatsu et al, 2000), using the 
primers AID13, AID14, AID15. 
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3.2. Flow cytometry analysis and cell sorting 
For cell sorting or flow cytometry analysis, bone marrow B lymphocytes were purified 
(FACS Aria cell sorter) as Ly6c-NK1.1-DX5-B220+ c-Kit+ (pro-B) and Ly6c-NK1.1-DX5-
B220+CD25+ (pre-B) cells.  Purity >97% was verified by flow cytometry re-analysis.  
Anti-B220 antibodies were conjugated either with PeCy7 (Bioscience), FITC or APC 
(Becton Coulter).  Anti-IgM antibodies (Southern Biotechnologies) were conjugated  
with PE or biotin.  APC anti-CD19 antibody was from Becton Coulter.  PE-anti-CD25, 
biotin-anti-CD43, PE-anti-CD117, and biotin-anti-pre-BCR antibodies were all from 
Pharmingen.  APC-streptavidin (Pharmingen) or ECD-streptavidin (Immunotech) was 
used to conjugate with biotin.  FITC- or biotin-conjugated anti-Ly6.C (Becton Coulter), 
-NK1.1 and -DX5 (both from Pharmingen) antibodies were used in a dump channel to 
remove contaminating NK and dendritic cells.  Antibodies for FACS were from 
Pharmingen (IgG1-PE, IgE-PE, IgG2b-biotin, IgG3-PE, streptavidin-PE). 
3.3. Gene expression analysis 
For qPCR analysis, 2.5 µl cDNA (ten-fold dilution series) was mixed with primers and 
SYBR Green PCR master mix (Becton Dickinson).  All oligonucleotides were 
designed to yield 70-130 bp PCR fragments.   Oligonucleotides for c-myc and β-actin 
were as described (Campanero et al., 2000).  Primers for cd19 were cd19 sense (s) 
(5ʼ-AGTACGGGAATGTGCTCTCC-3ʼ) and cd19 antisense (as) (5ʼ-GGACTTGAATGC 
GTGGATTT-3ʼ), E2a-s (5ʼ-ATACAGCGAAGGTGCCCACT-3ʼ) and E2a-as (5ʼ-CTCAA 
GGTGCCAACACTGGT-3ʼ) for tcfe2a, Ebf1-s (5ʼ-CTATGTGCGCCTCATCGACT-3ʼ) 
and Ebf1-as (5ʼ-CATGATCTCGTGTGTGAGCAA-3ʼ) for ebf1, Flt3-s (5ʼ-CAGCCGCA 
CTTTGATTTACA-3ʼ) and Flt3-as (5ʼ-GGCTTCGCTCTGAATATGGA-3ʼ) for flt3.  Each 
gene was analysed in triplicate.  cDNA samples and reagents were run on an ABI 
Prism 7900HT.  Data were analysed with SDS 2.2 sequence detection systems. 
3.4. Luciferase activity assay 
The murine ebf1 α, ebf1 β , e2a and pax5 promoters were amplified by PCR using 
the following primers:  ebf1-α-FWD: 5ʼ-TAAGAGCGCGGAACTGTCC-3ʼ, ebf1-α-REV: 
5ʼ-GCTGAAGAATCTGCCAGAAGTT-3ʼ, ebf1β-FWD 5ʼ-CTAGAATGCCCATTCC 
CTTG-3’, ebf1β-REV 5’-CCTTTTCTTGTGGAAAAATC-3’, e2a-FWD 5ʼ-
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CCGCTCGAA CACATAACACC -3ʼ, e2a-REV 5ʼ-GGAAGGTTGGAAGTTCTGAGG-
3’, pax5-FWD 5ʼ-TGCGGGCACTCGGAGCCGAA-3’, pax5-REV 5’-
GATACTAGCACTGGGTAGTG-3’, respectively, cloned into the EcoRI site of the 
Topo 2.1 vector (Invitrogen) and subcloned into the NheI-BglII site of the pGL3-
Control vector (Promega) upstream of the luciferase gene to generate pGL3-ebf1α, 
pGL3-ebf1β, pGL3-e2a and pGL3-pax5 vectors. 
For luciferase assays, HEK-293T cells were plated in 24-well plates at 2 x 105 
cells/well, cultured to subconfluence, and cotransfected using JetPeI reagent 
(PolyPlus) with 500 ng pGL3-ebf1α, pGL3-ebf1β, pGL3-e2a and pGL3-pax5 or pGL3 
control vector and increasing amounts of pRV-IRES-gfp-c-myc expression vector.  At 
24 h post-transfection, firefly and renilla activity were measured using the Dual-
Luciferase Reporter Assay (Promega).  
 
L1-2 cells (5 x 106) were transfected by electroporation using 5 µg of pGL3-ebf1α, 
pGL3-ebf1β, pGL3-e2a and pGL3-pax5 or pGL3 control vector and increasing 
amounts of pRV-IRES-gfp-c-myc expression vector.  At 18 h post-transfection, firefly 
and renilla activity were measured using the Dual-Luciferase Reporter Assay. 
 
Murine aicda regions were amplified by PCR using the following primers: R1.Fwd, 5ʼ-
GAAGATCTTGTGTCTCAGTATGTCATTCC-3ʼ, R1.Rev, 5ʼ-ATGCCATGGGGAGCAC 
ATGCACAAGCAGAT-3ʼ; R4.Fwd, 5ʼ-GACGCGTGGAACTCTCTGTAACCTC 
GGGC-3ʼ, R4.Rev, 5ʼ-CGACGCGTGCAAGGCAGCGAGGACAGAG-3ʼ; I1.Fwd, 5ʼ- 
CGCGGATCCGACAGTGGAGAGACACAG-3ʼ,  I1.Rev, 5ʼ- CCGCTCGAGGGTAAGG 
AGGACTTTG CTAG-3ʼ cloned into the BglII-NcoI, MluI-NheI and BamHI-XhoI sites, 
respectively, of the pGL3-empty vector (Promega), up- or downstream of the 
luciferase gene to generate vectors pGL3-R1, pGL3-R1-I1, pGL3-R1-R4, pGL3-R1-
R4-I1. For luciferase assays, HEK 293T cells were plated in 24-well plates at 2 x 105 
cells/well, cultured to subconfluence, and cotransfected using JetPeI with 500 ng of 
pGL3-R1, pGL3-R1-I1, pGL3-R1-R4 or pGL3-R1-R4-I1 and increasing amounts of 
pRV-IRES-gfp-c-myc expression vector.  At 24 h post-transfection, firefly and renilla 
activity were measured using the Dual-Luciferase Reporter Assay.  M12 cells were 
cotransfected by electroporation using 10 µg of pGL3-R1, pGL3-R1-I1, pGL3-R1-R4 
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or pGL3-R1-R4-I1 and increasing amounts of pRV-IRES-gfp-c-myc expression 
vector.  At 18 h post-transfection, firefly and renilla activity were measured as above.  
Results were represented as relative luciferase units or x-fold activation compared 
with empty vector. 
3.5. ChIP assays 
Experiments were performed following the protocol of the ChIP assay kit (Active 
Motif).  Briefly, L1-2 and M12 B cell lines were crosslinked with formaldehyde (1% 
final concentration), and incubated (room temperature, 20 min).  After sonication, 
rabbit polyclonal anti-c-Myc N262 antibody (sc-764, Santa Cruz) or pre-immune 
serum was used to precipitate chromatin from 2 x 106 cells.  Immunoprecipitated 
DNA and input samples were analysed with SYBR Green RT-PCR Kit (Applied 
Biosystems) and the percentage of enrichment relative to the amount of input 
chromatin was determined as 2(Ct input – Ct antibody).  Primers flanking E-box5 in the 
ebf1 α promoter were: E5-FW (5ʼ-CCTCAGCTCGTTCTGAGAGG-3ʼ) and EB5-REV 
(5ʼ-ACTCGCAGGAGGTAGAG AACG-3). 
3.6. Electrophoretic mobility shift assays (EMSA) 
EMSA was performed with labelled double-stranded (ds) oligonucleotides 
encompassing E-boxes from the ebf1 α and dhfr promoters.  pcDNA3-c-Myc and 
pcDNA3-Max were in vitro-translated (IVT) using TNT-coupled reticulocyte lysate 
systems (Promega).  Binding reactions between IVT proteins and labelled probes 
(1 ng) were performed as described (Kuhn, et al. 1995), except that 0.25x TBE was 
used.  Unlabelled oligonucleotide competitors (100 ng) and either 1 mg anti-c-Myc sc-
764 or 1 mg anti-c-Myb sc-517 antibody (both from Santa Cruz) were used.  
Ds oligonucleotides used: dhfr-I-wt (5ʼ-GGCGCGACACCCACGTGCCCT-3ʼ and 5ʼ-
AGAGAGGGCACGTGGGTGTCG-3ʼ), EB5-wt (5ʼ-GGTCCTACCCACGTTGACTG 
CAGT-3ʼ and 5ʼGAGACTGCAGTCAACGTGGGTAGGA-3ʼ), EB5-mut (5ʼ-GGTCCTAC 
CCTTGCTGACTGCAGT-3ʼ and 5ʼ-GAGACTGCAGTCAGCAAGGGTAGGA-3ʼ), 
EB505-wt (5ʼ-CGTTTCCTCACCTGTACAATGGGAGTGG-3ʼ and 5ʼ-GTCCACTCCCA 
TTGTACAGGTGAGGAAA-3ʼ), EB505-mut (5ʼ-CGTTTCCTCTCTTATACAATGGGA 
GTGG-3ʼ and 5ʼ-GTCCACTCCCATTGTATAAGAGAGGAAA-3ʼ). Complementary 
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oligonucleotides were mixed at an equimolar ratio in 10 mM Tris (pH 7.5)-50 mM 
NaCl, heated to 65°C, and annealed by slow cooling to room temperature.  Double-
stranded oligonucleotides (100 ng) were labelled by a Klenow fill-in reaction. 
3.7. Spleen B cell culture 
Homogenised single-cell suspensions from c-mycfl/+;cd19cre/+rosa26egfp/egfp, 
c-mycfl/flcd19cre/+rosa26egfp/egfp and c-mycfl/fl;cd19cre/+;rosa26egfp/egfp;IgK-AID were 
depleted of red blood cells by hypotonic lysis and stained with Pecy7-conjugated anti-
B220 monoclonal antibody (Pharmingen).  B lymphocytes were then sorted by flow 
cytometry (Coulter) based on dual cell surface expression of B220 and GFP.  After 
sorting, purity was monitored by FACS and was usually >98%.  Sorted B lymphocytes 
were cultured in RPMI medium supplemented with 15% foetal bovine serum, 1 mM 
L-glutamine, 1 mM penicillin/streptomycin, 50 µM β-mercaptoethanol and stimulated 
with lipopolysaccharide (LPS; 5 µg/ml) or anti-CD40 (10 µg/mL, Pharmingen) plus 
interleukin-4 (20 ng/mL, R&D) for 4 days at 37ºC.  Cells were collected on day 4 for 
surface Ig analysis by FACS, after staining with PE-anti-mouse IgG1, IgG2b, IgG3 
(Bioscience) and PECY7-anti-mouse CD45R (B220; clone RA3-6B2) rat mAb (BD 
Biosciences). 
3.8. ELISA assays 
Specific ELISA in 96-well-plates coated with polyclonal goat Ab F(ab)2 against the 
respective mouse isotype was used to measure Igγ1, Igγ2b, Igγ3, and Igε in culture 
supernatants of in vitro-stimulated spleen c-mycfl/+;cd19cre/+rosa26egfp/egfp, 
c-mycfl/flcd19cre/rosa26egfp/egfp and c-mycfl/fl;cd19cre/+;rosa26egfp/egfp;IgK-AID B cells. 
Serial two-fold dilutions (1:3 to 1:9) of supernatants were added (50 µl/well) to the 
plates and incubated (1 h, 25°C).  After washing, biotin-labelled isotype-specific mAb 
were added and developed using horseradish peroxidase-streptavidin.   The 
concentration of the Ig isotypes was determined by interpolation using a calibrated 
standard curve for each isotype.  Assays were performed in triplicates 
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4. Results I 
4.1. c-myc conditional knockout  
As c-myc inactivation in the germ line is lethal at embryonic day 9.5-10.5, a 
conditional knockout mouse was developed in which c-myc inactivation is restricted 
to a specific cell type.  We used a c-mycfl/fl mouse with two loxP sites inserted 
between exons 2 and 3 in the mouse germ line c-myc locus (Fig. 7).  Mice 
homozygous for this mutation show no phenotype in the absence of Cre recombinase 
(de Alborán et al., 2001).  The c-myc floxed sequence is deleted by the expression of 
Cre recombinase, which triggers inactivation of the c-myc gene (de Alborán et al., 
2001). 
 
Figure 7.  Targeting of the c-myc allele.  Targeting construct containing exons 2 
and 3 flanked by loxP sites (red triangles).  When Cre recombinase is expressed, 
directed by a specific promoter, the region between the loxP sites is excised.  Light-
colored boxes are non-coding exons. 
 
To study the role of c-Myc in early B cell differentiation, we conditionally inactivated 
the c-myc gene in developing B lymphocytes by breeding c-mycfl/fl mice with mb-1cre/+ 
knock-in mice (Hobeika et al., 2006), in which Cre recombinase expression is 
controlled by the endogenous promoter of the Igα chain (mb-1) gene from the earliest 
stage of B lymphocyte differentiation (pro- to pre-B cells) (Hobeika et al., 2006), 
leading to c-myc deletion in these B cell populations. 
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Fig 8. Scheme of the c-mycfl/fl mb-1cre/+ mouse model 
 
4.2. c-Myc is necessary for B lymphocyte differentiation 
Previous work in our laboratory using flow cytometry to analyse B cell populations 
from BM and spleen (Hardy et al., 1991) of c-mycfl/fl mb-1cre/+ mice showed that c-myc 
inactivation affects B cell differentiation.  Deletion of the c-myc gene at early 
differentiation stages led to a developmental defect at the pro- and pre-B cell 
transition to the immature B cell stage (Fig. 9A) that affected the mature population in 
the spleen (B220+IgM+ B cells) (Fig 9B).  In addition, the absolute number of 
B lymphocytes (B220+) in c-mycfl/fl mb-1cre/+ mouse BM was four-fold lower than in 
controls (0.4 x 106 vs 1.8 x 106) (Fig. 9C).  c-mycfl/fl mb-1cre/+ mouse spleens showed 
a 34-fold decrease (0.24 x 106 vs 8.1 x 106) in the number of mature B lymphocytes 
compared to controls (Fig. 9C).  These results indicated that c-Myc is necessary for 
the generation of pro- and pre-B cells. 
c-myc fl/fl  mb-1 cre/+
c-myc deletion in B lymphocytes
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A)                                                               B) 
 
C) 
 
Figure 9. c-Myc is necessary for B cell differentiation.  A) Single-cell suspensions 
of c-mycf/+;mb-1cre/+ and c-mycfl/fl;mb-1cre/+ BM were stained with anti-LyC6, Dx5, 
B220, IgM, c-Kit and CD25 to identify populations at different B cell differentiation 
stages.  B220+IgM-c-Kit+ (pro-B cells) and B220+IgM-CD25+ (pre-B cells) were gated 
on LyC6- and DX5- negative cells to remove B220+ non-B cells from BM.  B) Single-
cell suspensions of c-mycfl/fl;mb-1cre/+ and c-mycf/+;mb-1cre/+ spleen were stained with 
anti-B220 and -IgM to define the mature B cell population in spleen.  C) Total B cells 
from c-myc f/+;mb-1cre/+ and c-myc fl/fl;mb-1 cre/+ mouse BM and spleen. 
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4.3. Downregulated expression of tcfe2a, efb1 and pax5 expression in c-Myc-
deficient B cells 
To define the molecular mechanism by which c-Myc acts on B lymphocyte 
differentiation, we analysed sorted pro- and pre-B cells for the expression of key 
transcription factors involved in this process.  Quantitative PCR (qPCR) showed that 
e2a, ebf1, and pax-5 expression was slightly downregulated in sorted c-Myc-deficient 
pro-B cells, and that this effect was more pronounced in pre-B cells, probably due to 
the timing of c-myc deletion in mb-1cre/+ mice (Fig. 4A).  e2a-/-, ebf1-/- and pax-5-/- mice 
have a block at early stages of B cell development; Ebf1 shares some target genes 
with Pax-5 and transcriptionally regulates its expression, providing B cell identity 
(O'Riordan and Grosschedl, 1999).  Expression of the repressed Pax5 target gene 
flt3 (Hardy et al., 2007) was increased in pro- and pre-B cells from c-mycfl/flmb-1cre/+ 
mice compared to controls (Fig. 10). 
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Fig. 10. Gene expression Gene expression analysis by qPCR of sorted pro- 
(Ly6C-NK1.1-B220+c-Kit+) and pre-B cells (Ly6C-NK1.1-B220+CD25+) from 
c-mycfl/fl;mb-1cre/+ and c-mycfl/+;mb-1cre/+ mouse BM (mean ± SD for 3 mutant and 3 
control mice); numbers indicate x-fold change (2^(-ΔCt)). 
 
4.4. Promoter alignment screening for c-Myc binding sites  
To further study the role of c-Myc in the regulation of B lymphocyte development by 
controlling expression of genes important for B cell differentiation, we analysed the 
promoter regions and the regions 10 kb up- and downstream of the transcription start 
site of downregulated genes described above.  We used computer alignment analysis 
of human and mouse genomic DNA sequences to search for conserved c-Myc-
binding sites (E-boxes), we identified in e2a, ebf1α, ebf1β and pax5 promoter and/or 
first exonic and intronic regions (Fig. 11). We found, three E-boxes in e2a, two in 
ebf1α, three in ebf1β and four in pax5 promoters. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 11. Scheme showing reporter constructs used in luciferase assays.  
E-boxes are shown as black boxes; numbers indicate distance from transcription 
start site.  
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4.5. Luciferase assays 
To test whether c-Myc regulates the expression of the genes shown above, we 
cloned the promoter and regulatory regions into the pGL3-luc reporter vector, 
cotransfected them into the 293T HEK fibroblast cell line with different amounts of 
c-myc expression vector, and measured luciferase activity.  e2a, pax5 or ebf1β-
pGL3-luc constructs did not activate the luciferase gene in a c-Myc dose-dependent 
manner (Fig. 12)). 
 
 
 
 
 
 
 
 
 
 
Fig 12. ebf1β, e2a and pax-5 genomic loci do not respond to c-Myc. The 
indicated luciferase reporter constructs were cotransfected with different amounts of 
c-myc expression vector.  Luciferase activity was normalised with Renilla activity 
(relative luciferase units, RLU).  Figure representative of three independent 
experiments. 
 
Unlike the other three constructs, the pGL3-ebf1α construct showed induction of 
luciferase activity in a c-Myc dose-dependent manner, in both HEK 293T and L1-2 
lymphoid cell line (Fig 13A, B).  To determine which of the two E-boxes found in the 
ebf1α promoter was responsible for this activation, site-directed mutagenesis was 
performed in E-box5 (EBΔ5), located 200 bp upstream of the transcription start site.  
Luciferase assays showed complete abolishment of basal promoter activity and c-
Myc-dependent ebf1α transactivation in both cell lines (Fig. 13 A, B).  We conclude 
that c-Myc activates the ebf1α promoter and that E-box5 is implicated in this 
activation. 
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A)                       B) 
 
Fig 13. Luciferase assays. c-Myc transcriptionally regulates ebf1α. c-Myc dose-
dependent activation of ebf1α in transient transfection assays  in HEK 293T (A)  and 
in L1-2 B cell lines (B).  Luciferase activity was normalised with Renilla activity (RLU).  
Mean ± SD for three replicates in one representative experiment of 6 performed.  
***p<0.001 and *p<0.05. 
 
4.6. c-Myc binds to a region within the ebf1α promoter 
To determine whether c-Myc binds to ebf1α promoter, we performed a chromatin 
immunoprecipitation (ChIP) assay in the L1-2 lymphoid cell line.  Immunoprecipitated 
DNA was amplified using specific primers that flank E-box5.  Using PCR, we 
observed 10-fold enrichment in the DNA fragments immunoprecipitated with a c-Myc-
specific antibody compared to pre-immune serum (Fig 14).  This result indicated that 
c-Myc binds to a genomic region within ebf1α, containing E-box5. 
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Fig 14. ChIP assays.  L1-2 B cells were cross-linked and DNA was sonicated. 
Immunoprecipitation was performed with anti-c-Myc antibody (N262) or pre-immune 
serum (control).  Data show the mean of three independent experiments.  *p<0.05. 
 
4.7. c-Myc binds to the ebf1α promoter through E-box5 
To determine whether c-Myc bound specifically to E-box5, we perfomed EMSA 
assays.  c-Myc bound to oligonucleotides containing E-box5.  Mutated E-box5 or E-
box4 did not compete for c-Myc binding with unmutated E-box5, as determined using 
anti-c-Myc antibody (Fig.15).  As positive control for c-Myc binding to an E-box, we 
used the dhfr probe, located in a region 5´ of the dhfr gene (Mai et al., 1994).  We 
observed that E-box5 from ebf1 competed for c-Myc binding with oligonucleotides 
containing the dhfr E-box.  Mutated ebf1 E-box5 or E-box4 did not compete with the 
dhfr E-box. These data show that c-Myc directly regulates ebf1 transcription by 
binding to the E-box5 in the ebf1α promoter. 
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Fig 15.  EMSA assay. In vitro-translated c-Myc and Max proteins were incubated 
with oligonucleotides containing E-box5 from ebf1 (top) or the E-box from dhfr 
(bottom) and competitor oligonucleotides (indicated).  Lane 1, negative control 
without c-Myc/Max.  Lane 2, c-Myc/Max with no competitor.  Lanes 3 to 7, c-Myc/Max 
with different competitors.  Lane 8, c-Myc/Max with anti-c-Myc antibody.   Lane 9, 
c-Myc/Max with anti-c-Myb antibody (negative control).  Arrow indicates the shift of 
c-Myc/Max oligonucleotide complexes.  All experiments are representative of at least 
three independent assays. 
These data show that c-Myc directly regulates ebf1 transcription by binding to E-box5 
in the ebf1α promoter. 
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5. Results II 
5.1. New Role of c-Myc in terminal B cell differentiation 
It addition to this new role described for c-Myc in early B cell differentiation c-Myc has 
a critical function in terminal B cell differentiation (Shaffer et al., 2000; Lin et al., 
2000), although the mechanism by which it acts is unknown.  To address this 
question, we used the conditional c-mycfl/flcd19cre/+ mouse model, in which the 
endogenous promoter of the cd19 gene regulates expression of Cre recombinase 
(Rickert et al.,1997).  To distinguish between c-myc deleted and non-deleted B cells, 
we crossed c-mycfl/flcd19cre/+ mice with rosa26egfp/egfp reporter mice, in which green 
fluorescent protein (GFP) cDNA was inserted inside the rosa26 allele (Mao et al., 
2001).  Expression of Cre recombinase leads to deletion of the c-myc allele and of 
the stop codon inserted in the rosa26egfp gene, triggering GFP expression in c-Myc-
deficient B lymphocytes. 
5.2.  c-Myc-deficient mature B lymphocytes do not undergo class switch 
recombination in vitro 
To study the role of c-Myc in terminal B cell differentiation, we isolated mature 
(B220+GFP+) spleen B cells by sorting from c-mycfl/+cd19cre/+rosa26egfp/egfp and 
c-mycfl/flcd19cre/+rosa26egfp/egfp mice (c-mycfl/+ and c-mycfl/fl hereafter), and cultured them 
with anti-CD40 plus interleukin-4 (IL-4) or lipopolysaccharide (LPS) for 4 days.  After 
flow cytometry analysis, we found that c-Myc-deficient B lymphocytes have a severe 
impairment in the generation of IgG1+ cells (0.36% vs. 20.7% in c-mycfl/+) and IgG2b+ 
cells (3.44% vs. 43% in c-mycfl/+, control mouse) (Fig 16A).  In addition, we performed 
ELISA to test for IgG1 in c-mycfl/+ and c-mycfl/fl culture cell supernatants (Fig 16B).  We 
conclude that c-Myc-deficient B cells do not generate IgG1+ or IgG2b+ cells after in 
vitro activation. 
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Fig 16. Impaired class switch recombination in c-myc-deficient activated B 
cells.  A) Sorted B220+GFP+ spleen B cells from c-mycfl/fl and c-mycfl/+ mice were 
activated with anti-CD40 plus IL-4 or LPS and analysed by flow cytometry four days 
later.  B) ELISA for IgG1 detection in supernatants from cultures of activated B cells 
in A).  Representative data from one of at least three independent experiments. 
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Fig 17.  Normal expression of CD69 in c-Myc-deficient B cells.  B220+GFP+ 
mature B cells from c-mycfl/fl and c-mycfl/+ mice, activated with anti-CD40 plus IL-4 and 
analysed for CD69 expression at day 4.  Dashes lines indicate isotype control. 
 
We tested the expression of the activation marker CD69 and observed that activated c-
Myc-deficient B cells express normal levels, confirming previous findings (de Alborán 
et al., 2001). 
 
5.3. Normal expression of Iγ1-Cγ1 germline transcript in activated c-Myc-
deficient B lymphocytes 
 
Class switch recombination of immunoglobulin heavy chain is regulated by cytokine 
stimulation, which induces transcription from an intronic (I) promoter of a specific 
switch (S) region, giving rise to so-called germline transcripts (GLT) (Stavnezer et al., 
1986; Alt et al., 1988; Berton et al., 1989; Rothman et al., 1990; Lee et al., 2001).  
It was proposed that the function of GLT transcripts is to promote S region accessibility 
through cotranscriptional generation of R loops and possibly other structures that 
provide the substrates for the CSR process (Chaudhuri and Alt, 2004).  We used 
qPCR to determine germline transcript expression directed by the I promoter of each 
isotype.	  	  Total RNA was prepared at day 4 from activated c-mycfl/+ and c-mycfl/fl B cells 
and was reverse-transcribed and amplified using isotype-specific GLT primers.  We 
found that c-mycfl/fl B cells expressed normal Iγ1-Cγ1 germline transcript levels in 
response to anti-CD40 plus IL-4 compared to c-mycfl/+ cells (Fig 17A). ).  We detected 
low expression levels of other germline transcripts of different isotypes (two-fold 
reduction in Iε-Cε, five-fold reduction in Iγ3-Cγ3, and two-fold reduction in Iγ2b-Cγ2b 
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germline transcripts) in c-mycfl/fl compared to control B cells (Fig 17A, B). We conclude 
that c-Myc-deficient B cells express normal Iγ1-Cγ1 germline transcript levels but show 
impairment in the expression of Iε-Cε Iγ3-Cγ3 and Iγ2b-Cγ2b germline transcripts after 
in vitro stimulation). 
A)            B)	  
 
 
 
 
 
 
 
 
 
Fig 18.  Germline transcript expression.  qPCR of germline transcripts from sorted 
B220+GFP+ B cells from myc fl/+ and c-myc fl/fl mice, activated with anti-CD40 plus IL-
4 (A) or LPS (B); n = 6, *p>0.05 and  ***p>0.001. 
 
5.4. Lack of aicda induction in in vitro-activated c-Myc-deficient B cells 
Activation-induced cytidine deaminase, aicda (AID) has a critical role in both somatic 
hypermutation (SHM) and class switch recombination (CSR) (Muramatsu et al. 2000).   
AID is expressed by activated B cells, mainly in germinal centers (GC) of peripheral 
lymphoid organs (Honjo et al., 2002; Honjo et al., 2004) and initiates SHM and CSR by 
deaminating dC residues to yield dU:dG mispairs in DNA (Neuberger et al., 2003; 
Peled et al., 2008).  These U:G mispairs trigger DNA repair processes that  introduce 
mutations in V(D)J regions or DNA breaks, including double-stranded DNA breaks, 
and lead to non-classic non-homologous end-joining and CSR. 
We measured aicda transcription levels in in c-Myc-deficient B cells to test whether the 
failure in CSR could be due to a problem in aicda induction.  We sorted  B220+GFP+ 
B cells from c-mycfl/+ and c-mycfl/fl mice and activated them in vitro with anti-CD40 plus 
IL-4 for 4 days.  cDNA was analysed by qPCR with primers specific for aicda and c-
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myc genes.  We found that transcriptional levels of aicda were highly downregulated in 
c-Myc-deficient B cells compared to controls (21-fold compared to control) (Fig 18).  
We concluded that c-Myc-deficient B cells do not express aicda. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 19.  aicda downregulation in c-Myc-deficient B cells.  Sorted B220+GFP+ 
mature B cells from c-mycfl/fl and c-mycfl/+ mice were activated with anti-CD40 plus 
IL-4.  Control (black) and mutant cells (white).  Results were normalized to β-actin, 
n = 6. **p>0.01 and  ***p>0.001. 
 
5.5. c-Myc activates aicda expression through cytokine-responsive region 4 
The aicda locus has four regions, which are differentially bound by many transcription 
factors and regulate transcription in a cell-specific manner (Yadav et al., 2006).  The 
first region (R1) is located ~1 kb upstream of exon 1 and contains the minimal 
promoter.  It has sites for Stat6, Sp1, NF-κB, HoxC4 and Pax5 (Dedeoglu et al., 2004; 
Gonda et al., 2003; Park et al., 2009; Yadav et al., 2006).  The second region (R4) is 
found ~8 kb upstream of exon 1 in the mouse, and contains predicted binding sites for 
NF-κB, Stat6, C/EBP and Smad3/4 proteins (Tran et al., 2010; Yadav et al., 2006).  
This region responds to stimulation by anti-CD40 antibody and LPS, and upregulates 
aicda expression.  The third region is located in the first intron and has sites for 
negative and specific B cell regulatory factors (E proteins and Pax5) (Gonda et al., 
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2003;	  Sayegh et al., 2003; Tran et al., 2010; Yadav et al., 2006).  The fourth region is 
located ~6 kb downstream of exon 5 in the mouse (Tran et al., 2010; Yadav et al., 
2006) and appears to act as an enhancer (Crouch et al., 2007). 
We analysed aicda genomic locus and identified a conserved putative c-Myc 
regulatory binding site (E-box) within cytokine-responsive region 4 (R4).  To ensure 
the minimal activation of the promoter, we cloned the different regions, together with 
R1, into the pGL3-luc reporter vector (Fig 20A) and cotransfected them into the M12 
AID-expressing B cell line, with different amounts of the pRV-IRES-gfp-c-myc 
expression vector.  We subsequently measured luciferase activity and found c-Myc 
dose-dependent activation in the R1.R4 construct, which contains the E-box within 
the R4 cytokine-responsive region; in the R1.R4.I1 construct, which includes the I1 
inhibitory region, this activation was abolished.  There was no response in other 
constructs (Fig 19B). 
 
A)                       B) 
 
 
 
 
 
 
 
Fig 20. c-Myc activates aicda cytokine-responsive region 4 . A) Scheme showing 
the constructs tested in B).  Black boxes in R4 indicate E-box.  B) Luciferase reporter 
assays of constructs in A) in the M12 B cell line. Data are representative of two 
experiments. 
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5.6. c-Myc binds to a genomic fragment containing region 4 in vivo 
To determine whether c-Myc binds to the R4 region, we used a ChIP assay in the M12 
AID-expressing B cell line.  Immunoprecipitated DNA was amplified using specific 
primers that flank the E-box within region 4; using PCR, we observed four-fold 
enrichment of the DNA fragments immunoprecipitated with a c-Myc-specific antibody 
compared to pre-immune sera (Fig 21).  These data indicate that c-Myc activates 
aicda expression by binding to R4 containing the E-box. 
 
 
 
 
 
 
 
 
 
 
 
Fig 21. Chromatin immunoprecipitation in M12 cells. 	   Immunoprecipitation was 
performed with anti-c-Myc antibody or pre-immune serum as negative control (see 
Methods).  Data are representative of three independent experiments. 
 
5.7. In vivo rescue of class switch recombination in IgK-AID c-Myc-deficient B 
cells 	  
To determine whether aicda expression is sufficient to rescue class switch 
recombination in c-Myc-deficient B cells, we crossed the IgK-AID mouse (Robbiani et 
al., 2009) with cd19cre/+c-mycfl/flrosa26egfp/egfp mice (see above).  The resulting mice 
had c-Myc-deficient AID transgenic B cells in which ectopic expression of AID was 
controlled by immunoglobulin kappa chain enhancers (Fig 22A).  We isolated 
B220+GFP+ B cells from cd19cre/+c-mycfl/+rosa26egfp/egfp (c-mycfl/+), cd19cre/+c-
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mycfl/fl;rosa26egfp/egfp (c-mycfl/fl) and cd19cre/+c-mycfl/fl;rosa26egfp/egfpIgK-AID (c-
mycfl/flIgK-AID) mice, cultured them with anti-CD40 plus IL-4, and analysed the 
percentage of IgG1-expressing cells by FACS at day 4.  c-mycfl/flIgK-AID B cells were 
able to switch to the IgG1 isotype (8.34%), at difference from c-mycfl/fl IgG1+ 
cells(1.92%) (Fig 22B).  Using ELISA, we also tested for IgG1 in culture supernatants 
from these cells and found a seven-fold increase in c-mycfl/flIgK-AID (0.7 µg/mL) 
compared to c-mycfl/fl (0.1 µg/mL) (Fig 22C).  These data shows that ectopic 
expression of aicda in c-Myc deficient B cells is sufficient to rescue class switch 
recombination. 
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C) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22.  AID expression restores class switch recombination in c-Myc-deficient 
B cells.  A) Scheme showing the cd19cre/+;c-mycfl/+;rosa26egfp/egfp mouse model.  B) 
Flow cytometry analysis of surface IgG1 expression in cd19cre/+;c-myc 
fl/+;rosa26egfp/egfp (c-mycfl/+), cd19cre/+;c-mycfl/fl;rosa26egfp/egfp (c-mycfl/fl) and cd19cre/+;c-
mycfl/fl;rosa26egfp/egf IgK-AID (c-mycfl/fl;IgK-AID) B cells, activated with anti-CD40 plus 
IL-4 for 4 days.  Data are representative of at least three independent experiments.  
C) ELISA for IgG1 in supernatants from B cells in B).  n = 3, *p>0.05. 
 
5.8. Impairment of proliferation in activated c-Myc-deficient B lymphocytes 
The number of cell divisions is correlated with CSR (Hodgkin et al., 1996) and with AID 
expression (Rush et al., 2005).  Cells must carry out at least one replication round to 
express a switched isotype.  This process is associated with accessibility of the 
immunoglobulin locus.  Previous results with c-mycfl/flcd19cre/+ B cells showed that 
proliferation is impaired in c-Myc-deficient activated B cells (de Alborán et al., 2001).  
We monitored cell division with the dye CellTrace Violet (similar to CFSE) by flow 
cytometry analysis of fluorescence decay, and observed that activated c-mycfl/fl and 
c-mycfl/fl;IgK-AID B cells did not undergo even a single division (Fig 23A), at difference 
from c-mycfl/+ control cultures.  These results also correlated with cell counts for these 
cultures after treatment with anti-CD40 plus IL-4 or LPS at day 4 (Fig 23B). 
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Fig 23.  Activated c-Myc-deficient B cells do not proliferate.  Sorted B220+GFP+ 
spleen B cells from c-mycfl/+, c-mycfl/fl, and c-mycfl/fl;IgK-AID mice were stained with 
CellTrace Violet, followed by anti-CD40 plus IL-4 activation. Cells were counted A) and 
analysed by flow cytometry four days later B). n = 6, ***p>0.001 
 
5.9. Class switch recombination in c-mycfl/fl;IgK-AID B cells correlates with 
circle transcript expression 
Class switch recombination generates switched DNA circles that originate isotype-
specific transcripts from I promoters, termed “circle transcripts” (CT).  CT are produced 
in cells that not only express AID but also undergo class switch recombination 
(Kinoshita et al., 2001).  We tested whether the CSR rescue observed in FACS and 
ELISA correlated with CT expression (Iγ-Cµ) in B cells cultured from c-mycfl/fl;Igκ-AID 
mice.  We sorted B220+GFP+ spleen B cells from c-mycfl/+, c-mycfl/fl and c-mycfl/fl;IgK-
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AID, AID-deficient (AID-/-), and AID-deficient AID-transgenic (AID-/-;IgK-AID) mice and 
cultured them with anti-CD40 plus IL 4 for 48 h. We then re-sorted them by GFP 
expression to rule out possible contamination with non-c-Myc-deficient B cells (GFP-
negative) and analysed Iγ-Cµ CT and aicda expression by qPCR.  We observed a 10-
fold increase in Iγ-Cµ transcripts in c-mycfl/fl; Igκ-AID compared to c-mycfl/fl B cells (Fig 
24).  We also included AID-/- and AID-/-; IgK-AID B cells as negative and positive 
controls of rescue, respectively.  These results showed that AID expression in c-Myc-
deficient B lymphocytes is sufficient for IgG1 switching after in vitro anti-CD40 plus IL-4 
activation, in the absence of cell division 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24.  Circle transcript expression in activated B cells.  Spleen B cells from 
c-mycfl/+, c-mycfl/fl, c-mycfl/fl;IgK-AID, AID-/- and AID-/-;IgK-AID mice were sorted by 
B220+GFP+ expression, activated with anti-CD40 plus IL-4, and re-sorted after 48 h 
by GFP expression.  cDNA was analysed by qPCR with specific primers to amplify 
Iγ-Cµ and aicda transcripts.  Data show x-fold change relative to c-mycfl/+ and are 
representative of two independent experiments. 
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6. DISCUSSION 
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6. Discussion 
Although the role of the proto-oncogene c-myc in the cell cycle and apoptosis has 
been studied extensively, its function in B cell development remains poorly understood, 
probably due to the lack of suitable mouse models of c-myc inactivation in developing 
B cells. 
 
In this study, we shed light on the role of the proto-oncogene c-myc in early stages of 
B lymphocyte differentiation, as well as during the critical process of B cell activation 
and class switch recombination through specific activation of target genes.  Using two 
constitutive conditional mouse models in which c-myc is inactivated at different times, 
we attempted to determine whether c-Myc has a function in B lymphocyte 
development.  In the first model, we bred c-mycfl/fl with mb-1cre/+ mice, in which Cre 
recombinase expression is controlled by the Igα promoter (mb-1), inactivating c-myc at 
early steps of B cell differentiation (Vallespinós et al., 2011, in press).  In the second 
model, we used a c-mycfl/f;cd19cre/+ mouse to delete c-myc specifically in mature B 
lymphocytes, and crossed it with a rosa26egfp/egfp reporter mouse, to distinguish 
between deleted and non-deleted B cells (Baena et al., 2005) 
 
To study the role of c-myc in early B lymphocyte differentiation and to define the 
molecular mechanism by which c-Myc controls these process, our starting point was 
the observation in our laboratory that c-mycfl/fl;mb-1cre/+ mice showed a blockade in 
B cell development at the pre- (B220+CD25+) to immature (B220lowIgM+) B cell stages 
(Fig 9A).  Pro-B cells appeared to be less severely affected, probably due to the time 
at which c-myc deletion occurs.  These results correlated with the absence of c-Myc-
deficient mature B cells in c-mycfl/fl;mb-1cre/+ mouse spleens (Fig 9B), since the small 
percentage of B220+IgM+ B cells in spleen were not deleted (not shown) and could 
thus be considered wild type cells.  A similar blockade was described in mb-1-cre-
dependent deletion of the c-myb gene (Fahl et al., 2009), considered a transcriptional 
regulator of c-myc (Kumar et al., 2003).  Our results are thus in agreement, and place 
c-Myc in the context of c-Myb B cell regulation via Ebf1. 
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In addition to its role in ebf1 regulation, c-Myc is implicated in the control of apoptosis 
and proliferation of pro- and pre-B cell populations (Vallespinós et al., 2011).  To 
determine whether c-Myc acts in B cell development by modulating specific B cell 
genes, we analysed the expression of transcription factors known to regulate B lineage 
and commitment (O'Riordan and Grosschedl, 1999).  We found a decrease in e2a, 
ebf1, and pax5 transcripts from c-mycfl/fl;mb-1cre/+ pro-B cells compared to controls; 
these decreases were more notable in the pre-B cell compartment, due to the time of 
deletion.  These transcription factors are important regulators of B lymphocyte 
differentiation (Bartholdy and Matthias, 2004; Medina et al., 2004) and the knock-out 
mouse models also show a blockade at similar stages of B cell differentiation 
compared to c-mycfl/fl;mb-1cre/+ mice (Bain et al. 1994; Lin and Grosschedl 1995).  Our 
results therefore indicated a specific role for c-Myc in the regulation of the early B cell 
differentiation pathway. 
 
We observed no c-Myc transcriptional regulation of e2a or pax5 constructs in 
luciferase reporter assays (Fig 12); it is nonetheless possible that there is an indirect 
effect of c-Myc on their regulation.  Downregulation of ebf1 is described to negatively 
affect e2a expression levels, since ebf1-/- showed two-fold downregulated e2a 
transcripts, indicating a positive feedback loop (Zhuang et al., 2004). pax5 
downregulation in c-mycfl/fl;mb-1cre/+ pre-B cells can be explained by the downstream 
position of pax5 relative to ebf1 in the activation pathway (O'Riordan et al., 2004; 
Medina et al., 2004; Roessler et al., 2007). 
 
In the case of the ebf1α  construct, we found transcriptional activation in a c-Myc dose-
dependent manner when we assayed it in a human fibroblast cell line (HEK 293T) and 
an L1-2 murine pre-B cell line (Fig 13).  Moreover, activation was completely abolished 
when we specifically mutated the E-box 5 (E5).  Using ChIP and EMSA assays, we 
demonstrated that this E-box was directly implicated in the ebf1transactivation 
process, through c-Myc binding (Fig 14 and 15, respectively). 
 
The ebf1 gene has two promoters, ebf1α and ebf1β, which are differentially regulated 
in a hierarchical network in which E2a activates ebf1 expression by binding to the 
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ebf1α promoter; Ebf1 activates pax5 expression and Pax5 maintains ebf1 levels 
through activation of the ebf1β promoter (Roessler et al., 2007).  The contribution of 
the ebf1α promoter to total ebf1 transcript levels is small compared to that of the β 
promoter; however, we consider that this contribution is essential at early stages of B 
cell differentiation, due to the complex regulation of ebf-1 expression (Roessler et al,. 
2007).  A small amount of ebf1 (transcribed from the ebf1α promoter) triggers pax5 
expression, which in turn induces expression of large amounts of Ebf1 by activating 
the ebf1β promoter.  In addition, Ebf1 has a role in e2a activation, as ebf1-/- B cells 
show downregulated e2a expression (Zhuang et al., 2004).  We therefore propose that 
c-Myc, together with E2a, activates ebf1 (through the ebf1α promoter), which in turn 
activates pax5, thus triggering and maintaining the B cell differentiation program. 
 
These results identified ebf1 as a c-Myc target gene and illustrate a novel c-Myc 
function in the complex regulation of B lymphocyte development. 
 
Fig 25. Model of ebf1 regulation through c-Myc. 
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In many cell types, including B lymphocytes, c-myc expression must be downregulated 
to achieve terminal differentiation (Lachman and Skoultchi, 1984; Lin et al., 2000).  In 
B cells, however, this event is preceded by an increase in its expression.  To study the 
role of c-Myc in CSR, we used a c-mycfl/fl;cd19cre/+;rosa26egfp/egfp mouse model 
and analysed the behaviour of c-Myc-deficient B cells in culture after activation with 
anti-CD40 plus interleukin-4 or LPS. 
 
We observed severe CSR impairment in c-Myc-deficient cells compared to controls 
(Fig 16A, B).  We tested the activation status of these cells and confirmed expression 
of activation markers such as CD69 (de Alborán et al., 2001).  c-Myc-deficient B cells 
were therefore able to trigger the pathway that gives rise to expression of these 
markers at the membrane, and impairment was thus due to the implication of c-Myc in 
some step of the class switch recombination pathway. 
 
The class switch recombination process is triggered by specific cytokine stimulation, 
which promotes transcription through an intronic promoter (I) and gives rise to a so-
called sterile germline transcript (GLT) (Berton et al., 1989).  Synthesis of this GLT is 
absolutely necessary for correct development of the CSR process (Islam et al., 1994), 
and has been correlated with accessibility of the CH locus to the switch machinery 
(Stavnezer et al., 2000).  Abolishment of this transcript severely affects CSR (Jung et 
al., 1993; Zhang et al., 1993). 
 
We analysed GLT expression in the c-Myc-deficient B cells to determine whether the 
CSR impairment was due to a failure in GLT expression.  As shown in Fig 18, c-Myc-
deficient B cells expressed normal levels of Iγ-Cγ GLT, but the other GLT (such as 
Iγ2b-Cγ2b, Iγ3-Cγ3 and Iε-Cε appeared to be downregulated compared to controls.  
Since GLT expression levels correlated with CSR efficiency (Lee et al., 2001), we 
further analysed the IgG1 impairment in activated c-Myc-deficient B cells expressing 
Iγ-Cγ GLT, which were unable to carry out the CSR process. 
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CSR is a cell proliferation-coupled mechanism.  Activated B cells must undergo a 
certain number cell divisions to switch from IgM to another isotype (Hodgkin et al., 
1996; Hasbold et al., 1998; Hasbold et al., 1999).  We tested the ability of c-Myc-
deficient B cells to proliferate in the presence of anti-CD40 plus IL-4 by CFSE-like 
Violet CellTrace staining, and found that c-mycfl/fl mouse B cells did not proliferate for 
even a single cell division (Fig 23).  The proliferation requirement correlates with 
expression of an enzyme critical for CSR, activation-induced cytidine deaminase 
(aicda and the protein AID) (Muramatsu et al., 1999).  AID acts as a DNA deaminase, 
deaminating dC residues to dU in single-stranded DNA in the non-template DNA 
strand within the R-loop structure inside transcribed S region repeats (Xu et al., 2005).  
AID expression is absolutely necessary for CSR (Muramatsu et al., 2000) and its 
expression levels increase with the number of cell divisions (Rush et al., 2005).  To 
test whether AID levels were diminished, affecting CSR in c-Myc-deficient B cells, we 
analysed aicda expression in activated c-mycfl/fl B cells and observed a 10-fold 
decrease compared to control cells (Fig 19). This downregulation in aicda levels might 
thus reflect direct c-Myc regulation. 
 
The mechanisms that control AID expression are highly regulated, and AID 
deregulation results in translocations and malignant transformation of B cells (Ramiro 
et al., 2006; Kuppers et al., 2001) and T cells (Okazaki et al., 2003).  Nonetheless, the 
molecular pathways that govern the transcriptional regulation of aicda have not been 
completely elucidated.  Following B cell activation in vivo or in vitro through CD40 and 
the IL-4 receptor, a potent cascade of intracellular signal transduction pathways 
triggers aicda induction (Muramatsu et al., 1999; Jabara et al., 2002; Schrader et al. 
2005) through various transcription factors such as Pax5 (Gonda et al., 2003), E2a 
(Sayegh et al., 2003), Stat6, NF-κB (Dedeoglu et al., 2004) and HoxC4 (Seok-Rae et 
al., 2009).  Other negative modulatory factors such as Blimp1 and Id2 downregulate 
aicda and restrict its expression primarily to germinal centre B cells.  Our results 
identified aicda as a previously unreported c-Myc target gene and correlated the need 
for cell proliferation with CSR. 
 
To determine whether AID restoration was sufficient to restore CSR in c-Myc-deficient 
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B cells, we bred c-mycfl/fl;cd19cre/+;rosa26egfp/egfp with IgK-AID transgenic mice and used 
FACS to analyse IgG1 expression.  We also tested expression of circle transcripts as a 
hallmark of CSR (Kinoshita et al., 2001) and found 10-fold increased levels of Iγ1-Cµ 
expression transcripts in c-mycfl/fl;IgK-AID B cells compared to controls. 
Our findings showed partial rescue of IgG1 expression in AID-expressing c-Myc-
deficient B cells (Fig 22) in the absence of proliferation, and suggest a prominent role 
for c-Myc in the generation of a normal, potent immune response.  c-Myc is required 
not only for cell proliferation, but also for differentiation and CSR.  Our data show that 
cell proliferation and CSR are linked physiologically by c-Myc, although these functions 
can be uncoupled mechanistically.  The results highlight the fact that CSR can occur in 
the absence of proliferation, and that the mechanisms by which both processes are 
linked is controlled by c-Myc.  We thus postulate that c-Myc controls aicda expression 
while promoting cell proliferation, providing a fine-tuning mechanism to balance 
specific cell expansion and enhancement of a secondary immune response. 
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7. Conclusions 
1) Conditional inactivation of c-myc in developing B lymphocytes causes a blockade 
at the pro- to pre-B cell transition in c-mycfl/fl;mb-1cre/+ mice. 
 
2) c-Myc-deficient pro- and pre-B cells show downregulated expression of specific B 
cell transcription factors genes such as e2a, ebf1 and pax5. 
 
3) c-Myc  controls early stages of B lymphocyte differentiation through binding to the 
ebf1α promoter, and activating transcription of ebf-1. 
 
4) c-Myc-deficient B lymphocytes do not undergo CSR after in vitro activation. 
 
5) Activated c-Myc-deficient B lymphocytes express the CD69 activation marker, 
normal levels of Iγ1-Cγ1 germline transcripts and do not express aicda. 
 
6) c-Myc activates aicda transcription through binding to the R4 regulatory region. 
 
7) Ectopic expression of aicda in c-Myc-deficient B lymphocytes is sufficient to rescue 
CSR. 
 
8) CSR can occur in the absence of cell division. 
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8. RESUMEN 
8.1. Introducción 	  
El proto-oncogen c-myc fue descubierto como el homologo celular del oncogén v-myc, 
perteneciente al retrovirus MC29.  
La proteina c-Myc forma parte de la familia de factores de transcripción bHLHZ 
implicados en la regulación de la proliferación, apoptosis y diferenciación celular 
(Blackwell et al., 1990; Landshulz et al., 1988; Murre et al., 1989).  
La expresion de c-myc está altamente regulada tanto a nivel transcricional como post-
transcripcional (Jones and Cole, 1987; Brewer and Ross, 1988). Su expresión es casi 
indetectable en células quiescentes sin embargo, tras la exposición a diferentes 
mitógenos, se produce un aumento significativo y con ello, la célula comienza la 
transición G0/G1 hacía fase S (Kelly et al., 1983; Campisi et al., 1984). Una 
caracteristica típica de c-myc es que una desregulación de su expresión favorece la 
formación de tumores in vivo (Adams and Cory, 1985; Morgenbesser and DePinho, 
1994). Sólo en EEUU se estima que  1/7 de los canceres humanos que causan 
muerte al año, presentan alteraciones en la regulación de c-myc.   
c-Myc dimeriza con la proteina Max y forma un complejo protéico que se une al ADN a 
traves de la secuencia CACGTG denominada caja E y activa la transcripción de sus 
genes diana (Blackwoodand and Eisenman, 1991; Ayer and Eisenman, 1993; Amati 
and Land, 1994). 
Tambien se ha descrito la capacidad de c-Myc para inhibir la transcripción de 
numerosos genes, muchos de ellos, implicados en la salida de ciclo celular (Gartel 
and Shchors, 2003).  
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Además del importante papel desempeñado por c-Myc en proliferación y apoptosis, no 
menos importante, es su función en diferenciación celular. 
c-Myc se expresa normalmente en  células inmaduras en proliferación y una 
disminución en su expresión está vinculada con el desencadenamiento de la 
diferenciación celular (Chang et al., 2000; Henriksson and Luscher, 1996). Sin 
embargo, la expresion ectópica de c-myc bloquea la diferenciación terminal ne 
muchos tipos celulares, tanto in vivo como in vitro (Facchin and Facchin, 1998; Iritani 
and Eisenman, 1999).  Un ejemplo bien caracterizado de ello es el proceso de 
diferenciación terminal de las células B, en el cual la activación de blimp-1, cuya 
función en diferenciación B esta bien descrito, provoca una disminición de los niveles 
de expresión de c-myc (Lin et al., 1997).  
Durante el proceso de diferenciación de las células B, tienen lugar en una serie de 
eventos característicos, tales como, la expansión de unos pocos precursores en un 
gran número de células B inmaduras, que emigran a la periferia para formar parte del 
repertorio de células B maduras (Hardy and Hayakawa, 2001) ; el reordenamiento de 
los genes que codifican para el receptor de células B (Davis and Bjorkman, 1988) y el 
silenciamiento de aquellas células que expresan receptores afines a antígenos 
propios.  El desarrollo de células B maduras desde los precursores hematopoyéticos 
necesita de la acción coordinada de una serie de factores de transcripción, tales como  
Pu.1, E2a, Ebf1 y Pax5. De los cuales los tres últimos son clave en el proceso de 
diferenciación hacia célula B y del mantenimiento de la identidad B  (Zhuang et al., 
1994; Lin et al., 1995; Urbanek et al., 1994). Varios trabajos, han mostrado como la 
expresión de c-myc a lo largo del proceso de diferenciación de linfocitos B, está 
altamente regulada y ya que su expresión se requiere en estadios concretos ( de 
Alboran et al., 2001). Por tanto, hemos intentado dilucidar los mecanismos 
moleculares que subyacen a dicha necesidad de c-Myc, mediante el empleo de 
modelos de inactivación in vivo que permiten la inactivación de c-myc en un tipo 
celular específico mediante el empleo del sistema Cre-Lox. 
	   70	  
	  
El principal papel de las células B es la produccextrañas al propio organismo. Dicho 
pro. Esta productionas co la expansioniento de los genes que codifican para el 
receptor      ión de anticuerpos frente a diferentes moléculas extrañas al propio organismo, 
la cual tiene lugar mediante tres procesos bien diferenciados: La recombinación VDJ 
de los genes de las inmunoglobulinas, la hipermutación somática de las regiones 
variables (SHM) y el cambio de clase de isotipo (CSR). Tanto la SHM como el CSR 
requieren de la expresión de la proteína AID (cuyo gen se denomina aicda), la cual 
está implicada directamente en el proceso de hipermutación y de recombinación, ya 
que provoca mutaciones y roturas del ADN que conllevan a la alteración de la 
secuencia en las regiones variables de las inmunoglobulinas y al reordenamiento de 
las regiones constantes de las mismas, respectivamente. AID desamina las citosinas 
de las regiones variables y de las secuencias S, convirtiéndolas en uracilos y 
provocando un desemparejamiento G:U, que son reconocidos por la maquinaria de 
reparación del ADN y conllevan en ultimo lugar a la introducción de mutaciones (SHM) 
o a la rotura del ADN y posterior recombinación (CSR). 
El proceso de cambio de clase de isotipo (CSR) diversifica la función efectora del 
anticuerpo sin influir en la afinidad especifica por el antígeno y tiene lugar entre las 
secuencias repetitivas (S) de los genes que codifican para las regiones constantes 
(Stavnezer et al., 2000).  
Para que se lleve a cabo el cambio de clase, es necesario que exista transcripción a 
través de la región constante a la cual vaya a darse el proceso de recombinación. Con 
ello se produce un transcrito (GLT) que no codifica proteínas pero que es fundamental 
para que el cambio de clase se produzca con normalidad (Shinkura et al., 2003; Yu et 
al., 2003). Cada no de los promotores de las secuencias S se transcribe de forma 
diferencial en respuesta a una amplia variedad de mitógenos y citoquinas que dirigen 
de este modo el cambio de clase hacia uno de los isotipos en particular (Stavnezer, 
2000). Uno de los mecanismos que controlan el cambio de clase (CSR), consiste en la 
regulación específica de la expresión de  AID.  	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Además existe una relación bien documentada entre la proliferación celular y el 
proceso de CSR, ya que se ha observado un incremento en el proceso de cambio de 
clase en aquellas células B que han llevado a cabo un mayor numero de divisiones. 
que la expresión de AID está vinculada al número de divisiones celulares (Tangye and 
Hodgkin PD., 2004). Esto se explica mediante la unión existente entre los niveles de 
expresión de AID y el número de divisiones que tiene lugar en una misma célula 
(Rush et al., 2005). Ya que c-Myc juega un papel crucial en proliferación y que ésta es 
necesaria para el proceso de CSR, hemos querido profundizar en los mecanismos 
moleculares que gobiernan dicho proceso, mediante el empleo de modelos de 
inactivación de c-myc in vivo. 
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8.2. Resultados 
Modelos constitutivos de inactivación de c-myc 
Debido a la letalidad embrionaria  del knock-out de c-myc en línea germinal de ratón 
(Davis et al., 1993), hemos utilizado un modelo de inactivación condicional ( de 
Alborán et al., 2001) que nos permite estudiar la función de c-Myc en cada uno de los 
tipos celulares de interés. En el caso de células B inmaduras, hemos utilizado el 
modelo c-myc fl/fl mb1 cre/+  en el cual inactivamos c-myc específicamente en los 
estadios de pro y pre-B en médula ósea. 
Para llevar a cabo el estudio de la función de c-Myc en el proceso de cambio de clase 
(CSR), hemos utilizado el modelo c-myc fl/fl; cd19 cre/+; rosa26 egfp/egfp en el que la 
eliminación de c-myc se produce en el estadio de célula B madura y conlleva la 
expresión de GFP como marcador reportero. 
 
c-Myc es necesario para la diferenciación B 
Análisis previos en nuestro laboratorio, mostraron que la eliminación condicional de c-
myc en linfocitos de médula ósea, provoca un bloqueo en la diferenciación desde los 
estadios de pro-B y pre-B hasta células B inmaduras (Vallespinós et al., 2011), 
indicando por ello que c-Myc es necesario para la generación de pro-B y pre-B. 
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 Disminución de la expresión de los factores de transcripción tcfe2a, e2a, ebf1 y 
pax5 en células B deficientes en c-Myc 	  
A través del análisis de expresión génica de células pro-B y pre-B deficientes en c-
Myc, encontramos una disminución en la expresión de los factores de transcripción 
e2a, ebf1 y pax5, los cuales son fundamentales en el proceso de diferenciación y 
mantenimiento de identidad de células B. 
 
Estudio de los promotores y regiones reguladoras de los factores de 
transcripción tcfe2a, e2a, ebf1 y pax5 y ensayos de reportero de luciferasa 	  
Mediante el empleo de programas informáticos de alineamiento y estudio de 
secuencias de ADN, encontramos sitios de unión de c-Myc ( cajas E), en cada uno de 
los promotores de los genes tcfe2a, ebf1 y pax5.   
Para comprobar si c-Myc estaba activando la transcripción de alguno de estos genes 
mediante la unió a sus promotores, realizamos ensayos de reportero de luciferasa y 
comprobamos que ni el promotor de e2a ni el de pax5 eran activados por c-Myc. Sin 
embargo, el promotor proximal de ebf1, ebf1α  mostraba una activación del gene de 
luciferasa dependiente de c-Myc.Con ello podíamos concluir que c-Myc activa la 
expresión de ebf1 a través del promotor ebf1α. 
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c-Myc se une a la caja E5 del promotor α del gen ebf1 
 Mediante el empleo de la técnica de co-inmunoprecipitación de cromatina (ChIP) en 
la línea celular pre-B L1-2, confirmamos que c-Myc se une al promotor ebf1α in vivo. 
Mediante el uso de la técnica de EMSA comprobamos como c-Myc se une 
específicamente a la caja E 5 contenida en el promotor distal del gen ebf1. 
Así pues, podemos afirmar que c-Myc regula directamente la expresión de ebf1 
mediante la unión a una caja E situada en su promotor distal (ebf1α). 
 Linfocitos B deficientes en c-Myc no llevan a cabo el proceso de cambio de 
clase (CSR) in vitro 
Para estudiar el papel que desempeña c-Myc en la diferenciación terminal de los 
linfocitos B, aislamos células B maduras GFP+ B220+  de bazos de ratones c-myc fl/+ y 
c-myc fl/fl y las activamos en presencia de anti-CD40 más interleuquina 4 o de LPS.  
Tras 4 días en cultivo, analizamos la expresión de IgG1 y de IgG2b en membrana y 
comprobamos que las células deficientes en c-Myc no expresaban ninguno de los dos 
isotipos a los cuales dan lugar ambas activaciones. 
También comprobamos, la expresión de marcadores de activación en estas células y 
observamos que las células c-myc fl/fl expresan niveles normales de CD69 comparado 
con las células control.  
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Los linfocitos B activados deficientes en c-Myc expresan niveles normales de 
“germline transcripts” de IgG1 
El cambio de clase están regulado por diferentes citoquinas que determinan la 
transcripción de un determinado promotor de una de las regiones S, dando lugar al 
denominado “germline transcript” (GLT)  (Stavnezer et al., 1986; Lee et al., 2001; 
Chaudhuri y Alt, 2004). 
Analizamos mediante qPCR la expresión de GLT en las células deficientes en c-Myc y 
comprobamos que tenían niveles similares de IgG1 comparado con las células 
control. Sin embargo, presentaban niveles disminuidos de otros GLT. 
Ausencia de la expresión de aicda en linfocitos B deficientes en c-Myc y 
activados in vitro 
Aicda desempeña un papel fundamental en los procesos de hipermutación somática 
(SHM) y de cambio de clase (CSR) (Muramatsu, M. et al. 2000).  
Se expresa en células B activadas, principalmente en los centros germinales de los 
órganos linfoides periféricos (Honjo et al., 2002; Honjo et al., 2004). 
Para comprobar si el fallo en CSR en las células deficientes en c-Myc era debido un 
problema en la expresión de aicda, aislamos células B de ratones  c-myc fl/+ y c-myc fl/fl  
y las activamos in vitro durante 4 días. Posteriormente analizamos por qPCR la 
expresión de aicda y observamos que los linfocitos deficientes en c-Myc no 
expresaban aicda. 
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c-Myc activa la expresión de aicda a través de la unión a una región reguladora 
(R4) implicada en la respuesta a citoquinas 
Aicda contiene 4 regiones implicadas en su regulación transcripcional. (Yadav et al., 
2006). De todas ellas, las regiones 4, que responde a estímulos de citoquinas y 
2,implicada en la especificidad de célula B y en la unión de factores represivos, fueron 
las que presentaron sitios de unión de c-Myc. Mediante ensayos de reportero de 
luciferasa, comprobamos que la región 4 era capaz de activar la transcripción en 
repuesta a c-Myc. Para asegurarnos que c-Myc estaba uniéndose a la región 
reguladora de aicda, realizamos ensayos de ChIP y observamos que c-Myc se une 
específicamente a una fragmento de ADN que contiene una caja E en la región 4. 
Rescate in vivo del CSR en células B de ratones IgK-AID deficientes en c-Myc 
Para determinar si la mera expresión de aicda era suficiente para llevar a cabo el 
proceso de cambio de clase en células deficientes en c-Myc, cruzamos los ratones 
cd19 cre/+ c-myc fl/fl; rosa26 egfp/egfp  con ratones transgénicos que expresaban la 
proteína AID bajo el control reguladores positivos de la cadena IgK. 
Aislamos células B de estos ratones y las activamos in vitro con anti-CD40 más 
interleuquina 4. Observamos un incremento de 4 veces en la cantidad IgG1 en la 
células deficientes en c-Myc, que expresaban AID de manera transgénica, con 
respecto a las células deficientes en c-Myc. 
Además, corroboramos por ELISA que estas diferencias en la producción de IgG1 
eran reales. 
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Las células B  deficientes en c-Myc activadas in vitro, no son capaces de 
proliferar 
El numero de divisiones celulares se ha correlacionado con el proceso de CSR  
(Hodgkin et al., 1996) y con la expresión de AID (Rush et al., 2005). Además se ha 
comprobado que las células necesitan llevar a cabo al menos una ronda de 
replicación para expresar niveles normales de GLT y para expresar en membrana una 
inmunoglobulina determinada. 
Ya que estudio previos mostraban que las células B deficientes en c-Myc y activadas 
in vitro, presentaban un fallo en el proceso de proliferación, quisimos comprobar hasta 
que grado las células eran incapaces de dividirse. Para ello, las marcamos con un 
reactivo análogo al CFSE ( Violet Cell trace) que nos indica el numero de divisiones 
que lleva a cabo cada célula en cultivo tras ser activadas con anti CD40 más 
interleuquina 4 y observamos que las células deficientes en c-Myc no realizaban ni tan 
siquiera una división celular durante los 4 días de cultivo. 
Pudimos concluir que las células deficientes en c-Myc, a pesar de no proliferar, eran 
capaces de llevar a cabo el cambio de clase en presencia de anti-CD40 mas 
interleuquina 4. 
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Expresión de transcritos circulares (CT) en células B deficientes en c-Myc que 
expresan AID de manera transgénica activadas in vitro 
El proceso de cambio de clase (CSR) conlleva la producción de ADN circulares tras la 
recombinación somática, los cuales expresan transcritos específicos a partir del 
promotor del isotipo al que la célula haya cambiado de clase. La expresión de estos 
transcritos es específica y demuestra que el proceso de cambio de clase se ha llevado 
a cabo (Kinoshita et al., 2001). 
Para comprobar que el rescate en la producción de IgG1 era real, analizamos la 
expresión de CT (Iγ1-Cµ)  en las células c-myc fl/fl; IgK IAD mediante qPCR y 
observamos un aumento de 10 veces con respecto a las células c-myc fl/fl . 
Todos estos resultados mostraron que la expresión en AID en células deficientes en c-
Myc era suficiente para llevar a cabo el cambio de clase hacia IgG1 en ausencia de 
división celular. 
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8.3. Conclusiones 
1-La inactivación condicional de c-myc in linfocitos B en desarrollo, provoca un 
bloqueo en la transición pro-B a pre-B en ratones in c-myc fl/fl; mb-1 cre/+ 
 
2- Los linfocitos pro-B y pre-B deficientes en c-Myc presentan una disminución en la   
expresión de los factores de transcripción e2a, ebf1 and pax5. 
 
3- c-Myc controla la diferenciación temprana de linfocitos B mediante la unión al  
promotor ebf1a, que promueve la activación del gene ebf1. 
 
4- Los linfocitos B deficientes en c-Myc no llevan a cabo el proceso de cambio de 
clase de isotipo tras la activación in vitro 
 
5- Los linfocitos B deficientes en c-Myc, expresan niveles normales del marcador de 
activación CD69 y del GLT Iγ1-Cγ1, pero no expresan aicda 
 
6- c-Myc activa la expresión de aicda a través de la unión a su región reguladora 4 
 
7- La expresión ectópica de aicda en células deficientes en c-Myc es suficiente para 
rescatar el cambio de clase.   
 
8- El proceso de cambio de clase puede tener lugar en ausencia de división celular 
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ABSTRACT 
c-Myc, a member of the Myc family of transcription factors, is involved in numerous 
biological functions including the regulation of cell proliferation, differentiation and 
apoptosis in various cell types.  Of all its functions, the role of c-Myc in cell 
differentiation is one of the least understood.  We addressed the role of c-Myc in B 
lymphocyte differentiation.  We found that c-Myc is essential from early stages of B 
lymphocyte differentiation in vivo, and regulates this process by providing B cell 
identity via direct transcriptional regulation of the ebf-1 gene.  Our data show that c-
Myc influences early B lymphocyte differentiation by promoting activation of B cell 
identity genes, thus linking this transcription factor to the EBF-1-Pax-5 pathway. 
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INTRODUCTION 
The generation of mature B lymphocytes from early lymphoid progenitors in the bone 
marrow (BM) is a well-defined process characterized by several cell stages in which a 
number of transcription factors play a prominent role (1).  In BM, pro-B cells (B220+c-
Kit+) begin sequential rearrangement of the immunoglobulin heavy chain locus gene 
segments (V, D and J) and differentiate into pre-B lymphocytes (B220+CD25+).  
Productive rearrangement of the heavy chain locus triggers light chain rearrangement 
and cell surface expression of both heavy and light chains (IgM).  This process gives 
rise to immature B cells (B220+IgM+) that migrate from the BM to secondary lymphoid 
organs to generate mature B lymphocytes (2). 
The transcription factors E2A, EBF-1, and Pax-5 have a critical function in early B cell 
commitment and differentiation (3).  Mouse models of gene inactivation have shown 
the central role of these transcription factors in these processes.  Gene inactivation of 
tcfe2a (4, 5) or ebf-1 (6) in mice leads to an early block in B cell differentiation, before 
the onset of immunoglobulin heavy chain rearrangement.  Both factors appear to work 
in synergy to activate B cell-specific B lymphocyte genes, conferring B cell identity on 
early lymphoid precursors (7).  E2A deficient pro-B cells are rescued by ectopic 
expression of EBF-1 in vitro but not by Pax-5 (8).  Inactivation of pax-5 in mice causes 
a block in early B cell differentiation (9) and impaired Vdistal-to-DhJh rearrangement 
(10).  Pax-5 regulates the expression of B cell-specific genes cd19 (11), blnk (12) 
cd79a (13) and represses the expression of genes incompatible with B lymphocyte 
differentiation (14).  Ectopic Pax-5 expression is not capable of promoting B cell 
differentiation in ebf-1-/- progenitors.  EBF-1 induces pax-5 gene expression and 
activates the B cell transcriptional program (15).  Taken together, a model has been 
proposed in which E2A, EBF-1, and Pax-5 act sequentially to promote commitment to 
B cell fate (7, 15). 
The Myc proteins (N-, L- and c-Myc) are members of a basic region/helix-loop-
helix/leucine zipper (bHLHZip) transcription factor family and are involved in many 
biological functions.  All Myc proteins heterodimerize with Max and bind to specific 
sites on the DNA (E-boxes) to regulate their target genes (16); of all its members, c-
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Myc is probably the best studied.  In humans and mice, c-Myc deregulation is well 
established as a primary cause of some cancers.  It is estimated that the c-myc proto-
oncogene is activated in 20% of all human cancers (17).  It is expressed in many cell 
types, as well as in early BM progenitors and during B lymphocyte differentiation (18). 
Accumulated in vivo and in vitro evidence shows that c-Myc participates in regulating 
cell proliferation, differentiation and apoptosis in many cell settings, including B 
lymphocytes (16).  During cell cycling, c-Myc promotes G0/G1-S transition by 
activating genes that encode proteins of the cyclin/cdk complexes and by repressing 
cell cycle inhibitors such as p21 or p27 in numerous cell types (19).  In murine B cell 
lymphoma lines, apoptosis induced through the B cell receptor correlates with 
inhibition of c-myc expression (20).  In mice, mature B lymphocytes lacking c-Myc 
show impaired proliferation and elevated levels of the cell cycle inhibitor p27, as well 
as greater resistance to apoptosis (21, 22).  c-Myc overexpression in transgenic 
mouse B cells leads to rapid lymphoma development and mouse death (23). 
Despite numerous studies of c-Myc, little is known about its function in B cell 
differentiation (24).  c-Myc downregulation is associated with cell cycle arrest and 
terminal differentiation in B lymphocytes and myeloid cells (25-27).  Here we address 
the role of c-Myc in early B lymphocyte differentiation, using several conditional mouse 
models.  Our data provide evidence that c-Myc influences B lymphocyte differentiation 
through the EBF-1/Pax-5 pathway, thus activating B cell identity genes.  Finally, our 
results place c-Myc in the context of transcription factors required for B lymphocyte 
differentiation. 
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MATERIALS AND METHODS  
Mice and genotyping.  Generation of c-mycfl/fl;mx-cre+ mice was described (28).  To 
generate c-mycfl/fl;mb1cre/+ mice, c-mycfl/fl were bred with mb1cre/+mice (29) and progeny 
crossbred to yield homozygous (c-mycfl/fl;mb1cre/+) and control mice (c-mycfl/+;mb1cre/+ 
or c-mycfl/fl;mb1+/+).  c-mycfl/fl;mx-cre+ or c-mycfl/fl;mb1cre/+ mice were bred with ikneo/+ 
mice (30) to generate ikneo/+;c-mycfl/fl;mx-cre+ or ikneo/+;c-mycfl/fl;mb1cre/+ mice, 
respectively.  Progeny were crossed to generate homozygous (ikneo/+;c-mycfl/fl;mx-cre+ 
or ikneo/+;c-mycfl/fl;mb1cre/+) and control mice (ikneo/+;c-mycfl/fl;mx-cre- or ikneo/+;c-
mycfl/+;mb1cre/+).  Mice were genotyped using a PCR-based analysis of tail genomic 
DNA (28).  Primers hcre-DIR (5'-ACC TCT GAT GAA GTC AGG AAG AAC-3'), hcre-
REV (5'-GGA GAT GTC CTT CAC TCT GAT TCT-3'), mb1in1 (5'-CTG CGG GTA GAA 
GGG GGT C-3') and mb1in2 (5'-CCT TGC GAG GTC AGG GAG CC-3') were used to 
amplify mb1-cre (hcre-DIR and hcre-REV) and mb1-wt alleles (mb1in1 and mb1in2).  
The knock-in allele (ikneo/+) was identified as described (30). c-mycfl/fl;mx-cre+ or c-
mycfl/fl;mb1cre/+ mice were bred with rosa26gfp/gfp “reporter” mice (31) to generate c-
mycfl/fl;mx-cre+;rosa26gfp/gfp or c-mycfl/fl;mb-1cre/+;rosa26gfp/gfp mice, respectively.  The 
rosa26gfp allele was genotyped as described (31). 
pIpC injections.  To induce c-myc deletion in c-mycfl/fl;mx-cre+ and ikneo/+;c-mycfl/fl;mx-
cre+ mice, 4- to 6-week-old animals received three intraperitoneal (i.p.) injections of 
polyinosinic-polycytidylic acid (pIpC, Amersham) (200 µg each) at two-day intervals, 
and were analyzed 3 days after the last dose. 
Flow cytometry analysis and cell sorting.  For cell sorting or flow cytometry analysis 
BM B lymphocytes were purified (FACS Coulter cell sorter) and/or analyzed as (Ly6c-
NK1.1-DX5-B220+c-Kit+IgM-) pro-B and (Ly6c-NK1.1-DX5-B220+CD25+IgM-) pre-B 
cells.  Purity >97% was verified by flow cytometry re-analysis.  Anti-B220 antibodies 
were conjugated either with PeCy7 (Bioscience), FITC or APC (Becton Coulter).  Anti-
IgM antibodies (Southern Biotechnologies) were conjugated either with PE or biotin.  
APC anti-CD19 antibody was from Becton Coulter.  PE-anti-CD25, biotin-anti-CD43, 
PE-anti-CD117, and biotin-anti-pre-BCR antibodies were all from Pharmingen.  APC-
streptavidin (Pharmingen) or ECD-streptavidin (Immunotech) were used to conjugate 
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with biotin.  FITC- or biotin–conjugated anti-Ly6.C (Becton Coulter), anti-NK1.1 
and anti-DX5 (both from Pharmingen) antibodies were used in a dump channel 
to remove contaminating NK and dendritic cells.   
BrdU labelling.  BrdU incorporation was assessed 2 h after a single intravenous BrdU 
injection (1 mg/15 g body weight, Sigma). (Ly6c-NK1.1-DX5-B220+c-Kit+IgM-) pro-B 
and (Ly6c-NK1.1-DX5-B220+CD25+IgM-) pre-B cells from mb1-fl/fl and mb1-fl/+ mice 
were sorted from BM, and BrdU incorporation measured using FITC- or PE-anti-BrdU 
monoclonal antibody (Becton Dickinson) or propidium iodide, following standard 
protocols.  The same protocol for BrdU incorporation was used for sorted B220+IgM-, 
and immature cells from mx-fl/fl and fl/fl control mice. 
Retrovirus production and transduction.  Plat-E cells were seeded (2 x 106 cells) in 
6 cm plates, 18-24 h before transfection with MIG-RI or MIG-EBF plasmids (3 µg) in 
the presence of FuGene 6 reagent (Roche Diagnostics).  Retroviral supernatants were 
collected 48 h post-transfection and filtered through a 45 µm low protein-binding 
syringe filter (Pall, Life Sciences).  Lin- precursors were purified from total BM 
suspensions with Streptavidin Dynabeads (Invitrogen) by incubation with a cocktail of 
biotinylated antibodies to lineage markers (B220, IgM, CD4, CD8, Ter119, Gr1 and 
CD11b, all from Pharmingen).  Cells were cultured at 106 cells/ml in 24-well plates in 
Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated FBS, 1 
mM L-glutamine and supplemented with recombinant murine stem cell factor (50 
ng/ml), recombinant murine IL-6 (5 ng/ml) and murine leukaemia inhibitory factor (103 
units/ml).  Stimulated Lin- cells were transduced by spin infection after 24 h in culture.  
Cells were resuspended in 1 ml fresh retroviral supernatant, supplemented with 10 
µg/ml polybrene (Sigma-Aldrich) and cytokines as above.  Cells were centrifuged 
(1136 xg, 90 min, 32ºC) and incubated (3-4 h).  Medium was replaced with IMDM 
containing 2% heat-inactivated FBS, 1 mM L-glutamine, 1 mM penicillin/streptomycin, 
0.03% w/v primatone RL (Sigma), 50 mM β-mercaptoethanol and supplemented with 
rSCF (10 ng/ml), rFlt3L, (10 ng/ml) and rIL-7 (10 ng/ml).  Transduction efficiency was 
monitored by flow cytometry at 48 or 72 h post-infection. 
VDJ recombination analysis.  Genomic PCR amplification of immunoglobulin genes 
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was performed with Vh-specific primers from Fuxa et al. (32); DJ primers were from 
Ehlich et al. (33).  GAPDH was used as loading control.  PCR products were 
electrophoresed and the bands quantified with ImageJ software.  For VDJ sequencing, 
PCR fragments were amplified with FastStart High Fidelity polymerase (Roche) and 
the VHJ558-JH3 band was cloned in PCRII-TOPO.  Sequences were analyzed with the 
IGMT Junctions Analysis program. 
Gene expression analysis.  For qPCR analysis, 2.5 µl cDNA (ten-fold dilution series) 
was mixed with primers and SYBR Green PCR master mix (Becton Dickinson).  All 
oligonucleotides were designed to yield 70-130 bp PCR fragments.  Oligonucleotides 
for c-myc and β-actin were as described (34).  Primers for cd19 were CD19 sense (s) 
(5ʼ-AGTACGGGAATGTGCTCTCC-3ʼ) and antisense (as) (5ʼ-GGACT 
TGAATGCGTGGATTT-3ʼ), E2A-s (5ʼ-ATACAGCGAAGGTGCCCACT-3ʼ) and E2A-
as (5ʼ-CTCAAGGTGCCAACACTGGT-3ʼ) for tcfe2a, EBF1-s (5ʼ-
CTATGTGCGCCTCAT CGACT-3ʼ) and as (5ʼ-CATGATCTCGTGTGTGAGCAA-3ʼ) for 
ebf-1, Flt3-s (5ʼ-CAGCCG CACTTTGATTTACA-3ʼ) and as (5ʼ-
GGCTTCGCTCTGAATATGGA-3ʼ) for flt3, Ikaros-s (5ʼ-TTGTGGCCGGAGCTATAAAC-
3ʼ) and as (5ʼ-TGCCATCTCGTTGTGGTTAG-3ʼ) for ikaros, Lef-1-s (5ʼ-
TCAGTCATCCCGAAGAGGAG-3ʼ) and as (5ʼ-CTCTGGCCTTGTCGT GGTAG-3ʼ) for 
lef-1, Pu-1-s (5ʼ-GGGATCTGACCAACTGGAG-3ʼ) and as (5ʼ-GCTGCCC 
ACGAAGGAGTAGTA-3ʼ) for spfi1, and Rag1-s (5ʼ-GTTGCTATCTCTGTGGCATCG-3ʼ) 
and as (5ʼ-AATTTCATCGGGTGCAGAAC-3ʼ) for rag1.  For the remainder of the 
genes, Pre-designed Applied Biosystems Micro Fluidic cards were used.  Each gene 
was analyzed in triplicate.  cDNA samples and reagents were run on an ABI Prism 
7900HT.  Data were analyzed with SDS2.2 sequence detection systems. 
Luciferase activity assay.  The murine ebf-1 α-promoter was amplified by PCR using 
the following primers: Ebf1-α 5: 5ʼ-TAAGAGCGCGGAACTGTCC-3ʼ and Ebf1-α 3:  
5ʼ-GCTGAAGAATCTGCCAGAAGTT-3ʼ, cloned into the EcoRI site of the Topo 2.1 
vector (Invitrogen) and subcloned into the NheI-BglII site of the pGL3-Control vector 
(Promega) upstream of the luciferase gene to generate the vector pGL3-Ebf1α.  All 
constructs were sequenced.  For luciferase assays, HEK-293T cells were cultured in 
24-well plates and cotransfected with 500 ng pGL3-Ebf1α or pGL3 control vector and 
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increasing amounts of pRV-IRES-GFP-c-Myc expression vector.  Renilla luciferase 
activity was used to normalize.  At 48h post-transfection, firefly and Renilla luciferase 
activity were measured using the Dual-Luciferase Reporter Assay (Promega). 
ChIP assays. Experiments were performed following the protocol of the ChIP assay kit 
(Active Motif).  L1-2 cells were crosslinked with formaldehyde (1% final concentration) 
and incubated (room temperature, 20 min).  Rabbit polyclonal anti-c-Myc N262 
antibody (sc-764, Santa Cruz) or pre-immune serum was used to precipitate chromatin 
from 2 x 106 cells. Immunoprecipitated DNA and input samples were analyzed with 
SYBR Green RT-PCR Kit (Applied) and percent enrichment relative to the amount of 
input chromatin was determined as 2(Ct input-Ct antibody). Primers flanking E-box5 were: 
EB5-FW (5ʼ-CCTCAGCTCGTTCTGAGAGG-3ʼ) and EB5-REV(5ʼ-
ACTCGCAGGAGGTAGAG AACG-3). 
EMSA. Assays were performed with labeled double-stranded (ds) oligonucleotides 
encompassing E-boxes from the dhfr and ebf-1 α promoters.  pcDNA3-c-Myc and 
pcDNA3-Max were in vitro translated (IVT) using TNT-coupled reticulocyte lysate 
systems (Promega).  Binding reactions between IVT proteins and labeled probes (1 
ng) were performed as described (35), except that 0.25x TBE was used.  Unlabeled 
oligonucleotide competitors (100 ng) and either 1 µg anti-c-MYC sc-764x or 1 µg anti-c-
MYB sc-517x antibodies (both from Santa Cruz) were used.  Ds oligonucleotides used: 
DHFR-I-wt (5ʼ-GGCGCGACACCCACG TGCCCT-3ʼ and 5ʼ-
AGAGAGGGCACGTGGGTGTCG-3ʼ), EB5-wt (5ʼ-GGTCCTACCCA 
CGTTGACTGCAGT-3ʼ and 5ʼGAGACTGCAGTCAACGTGGGTAGGA-3ʼ), EB5-mut (5ʼ-
GGTCCTACCCTTGCTGACTGCAGT-3ʼ and 5ʼ-GAGACTGCAGTCAGCAAGGGTAGG 
A-3ʼ), EB505-wt (5ʼ-CGTTTCCTCACCTGTACAATGGGAGTGG-3ʼ and 5ʼ-GTCCACTC 
CCATTGTACAGGTGAGGAAA-3ʼ), EB505-mut (5ʼ-CGTTTCCTCTCTTATACAATGG 
GAGTGG-3ʼ and 5ʼ-GTCCACTCCCATTGTATAAGAGAGGAAA-3ʼ).  Complementary 
oligonucleotides were mixed at an equimolar ratio in 10 mM Tris (pH 7.5)-50 mM NaCl, 
heated to 65°C, and annealed by slow cooling to room temperature. Double-stranded 
oligonucleotides (100 ng) were labeled by a Klenow fill-in reaction. 
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RESULTS 
c-Myc is necessary for B lymphocyte differentiation 
To study the role of c-Myc in B cell differentiation, we conditionally inactivated c-myc 
gene in developing B lymphocytes by breeding the c-mycfl/fl (fl/fl) (21) conditional 
mouse with mb-1cre/+ knock-in (29), mx-cre transgenic (36), and rosa26gfp/gfp “reporter” 
mice (31).  In c-mycfl/fl;mb1cre/+ mice (mb1-fl/fl), the mb1-cre allele is expressed from 
the earliest stage of B lymphocyte differentiation (29).  In c-mycfl/fl;mx-cre+ mice (mx-
fl/fl), Cre recombinase is induced after injection of interferon or polyinosinic-
polycytidylic acid (pIpC) and efficiently deletes c-myc in bone marrow (BM) (28).  In 
addition, in rosa26gfp/gfp;c-mycfl/fl;mb1cre/+ mice (gfp-mb1-fl/fl) and in rosa26gfp/gfp;c-
mycfl/fl;mx-cre+ mice (gfp-mx-fl/fl), the rosa26gfp/gfp allele expresses green fluorescent 
protein (GFP) following activation of the Cre recombinase (31) (supplemental Fig. 
S1A). 
To determine whether c-myc inactivation affects B cell differentiation, we used flow 
cytometry to analyze the B cell populations in the BM and spleen of mb1-fl/fl mice (37) 
(38).  Deletion of the c-myc gene at early differentiation stages led to a developmental 
defect at the pro- to pre-B cell transition in BM of mb1-fl/fl and gfp-mb1-fl/fl mice (Fig. 
1, A and B; supplemental Fig. S1B).  Analysis of Hardy fractions in these mice also 
revealed a developmental defect and a decrease in absolute numbers in Fraction B, C 
and C´ (Large pre-B cells) consistent with the time in which deletion of c-myc occurs 
(Fig. 1, C and D).  Similar results were obtained when CD19 was used as a B cell 
marker (supplemental Fig. S2, A-D).  The absolute number of B lymphocytes (B220+) 
in mb1-fl/fl mouse BM was four-fold lower than those of controls (0.4 x 106 vs 1.8 x 
106) (Fig. 1E).  mb1-fl/fl spleens showed a 34-fold decrease (0.2 x 106 vs 8.1 x 106) in 
the number of mature B lymphocytes (B220+IgM+) compared to controls (Fig. 1E).  
Genomic PCR analysis of these cells confirmed c-myc deletion (supplemental Fig. S1, 
D and E).  In vitro cultures of gfp-mb1-fl/fl mouse BM cells did not generate IgM+ B 
lymphocytes, suggesting that the absence of c-Myc in mb1-fl/fl and gfp-mb1-fl/fl mouse 
BM prevents generation of mature B cells in spleen (supplemental Fig. S3).  To test 
the apoptotic status of pro- and pre-B cells in mb1-fl/fl mouse BM, we monitored 
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apoptosis by flow cytometry using annexin-V, and found a two-fold (2.8% vs 6.1%) in 
pro-B cells and a twenty-five-fold increase in pre-B cells (0.9% vs 23.1%) from mb1-fl/fl 
mice compared to controls (Fig. 2A).  c-Myc appears to be necessary for pre-B cell 
survival in mb1-fl/fl mice, and thus to be required from early stages of B cell 
differentiation. 
To study the c-Myc requirement at later stages of B cell development, we injected pIpC 
to induce c-myc deletion in mx-fl/fl mouse BM.  Analysis of Hardy fractions showed a 
decrease in the absolute numbers from fraction A to fraction E (Fig. 1F and G and 
supplemental Fig. 2E, F and G).  Fraction F seems to be less affected consistent with 
our previous results in mature B cells (21) (Fig. 1, F and G).  Annexin-V staining 
showed an increase (35.8% vs 14.1%) in the relative numbers of apoptotic pro- and 
pre-B  (B220+IgM-) and immature B cells (B220+IgM+) (77.9% vs 27.6%) in mx-fl/fl 
mouse BM compared to controls (Fig. 2B).  Recirculating mature (B220++IgM+) B 
lymphocytes in mx-fl/fl mouse BM survived in the absence of c-Myc (26.6% vs 31.5%), 
consistent with results for c-mycfl/fl;cd19cre/+ mice (21), indicating that c-myc is 
dispensable for mature B lymphocyte maintenance (Fig. 1F and Fig. 2B).  The lack of 
early hematopoietic precursors (28) could also contribute to the decrease in the 
number of recirculating mature B cells in mx-fl/fl mouse BM (not shown).  These 
results indicate that c-Myc is necessary for the generation of pro- and pre-B cells and 
for maintenance of immature B lymphocytes. 
 
Cell proliferation in developing c-Myc-deficient B lymphocytes 
c-Myc promotes proliferation in many cell types, including B lymphocytes, by regulating 
cell cycle genes (19).  Pro- to pre-B cell transition is also characterized by cell 
expansion (39). To determine whether c-Myc inactivation affected cell proliferation, we 
monitored in vivo BrdU incorporation in mb1-fl/fl and pIpC-injected mx-fl/fl mice.  
Sorted pro- and pre-B lymphocytes from mb1-fl/fl mice still retain some capacity to 
proliferate compared to controls (54.5% vs 25.4% in pro-B and 51.5% vs 6.1% in pre-B 
BrdU+ cells) by flow cytometry analysis (Fig. 3A).  mx-fl/fl mouse pro- and pre-B cells 
showed a similar proliferative capacity (Fig. 3B). We did not observe significant 
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differences in proliferation in immature lymphocytes from mx-fl/fl mice (Fig. 3B).  We 
concluded that developing B lymphocytes have a reduced capacity to proliferate in the 
absence of c-Myc in vivo. 
 
Reduced levels of V(D)J recombination in c-Myc deficient B lymphocytes 
Sequential rearrangement of the V(D)J gene segments that encode the B cell receptor 
is linked intrinsically to B lymphocyte differentiation (2).  To determine whether the 
developmental defect in c-Myc-deficient B lymphocytes was characterized by a lack of 
or impaired immunoglobulin gene recombination, we analyzed V(D)J rearrangement by 
genomic PCR in sorted pro-B and pre-B cells.  We did not observe significant 
differences in Dh-to-Jh, Vhproximal-, and Vhdistal-to-DhJh rearrangements in purified pro-
B cells from mb1-fl/fl mouse BM compared to control cells (Fig. 3C, top panel, and Fig. 
3D, p>0.05).  In contrast, purified pre-B cells from mutant mice showed a slight 
decrease in Vhproximal- (1.9-fold) and Vhdistal-to-DhJh (2.4-fold) rearrangements 
compared to control mice (Fig. 3C, bottom panel, and Fig. 3D).  These differences 
between pro- and pre-B likely reflect the time in which c-myc deletion occurs.  Pro-B 
cells are undergoing c-myc deletion and pre-B cells have completed it. To see whether 
these recombination events were normal we sequenced some V(D)J rearrangements 
from mb1-fl/fl and mb1-fl/+ mouse B cells and observed no apparent differences 
between both populations (supplemental Table S1). 
 
Gene expression in c-Myc-deficient B lymphocytes 
To define the molecular mechanism by which c-Myc acts on B lymphocyte 
differentiation, we analyzed gene expression of key transcription factors involved in 
this process.  Quantitative PCR (qPCR) showed that tcfe2a, ebf-1, ikaros and pax-5 
expression was slightly downregulated in sorted c-Myc-deficient pro-B cells and this 
effect was more dramatic in pre-B cells.  This is likely due to the timing in which c-myc 
deletion occurs in mb-1-cre mice. (Fig. 4A). Interestingly, tcfe2a-/-, ebf-1-/- and pax-5-/- 
mice have a block at early stages of B cell development, as well as impaired V(D)J 
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recombination (4, 6, 9).  EBF-1 shares some target genes with Pax-5 and 
transcriptionally regulates its expression providing B cell identity (7).  Expression of 
Pax-5 target genes such as cd19 (11) was reduced and that of the repressed target 
gene flt3 (40) was increased in pro-B and pre-B cells from mb1-fl/fl mice compared to 
controls (Fig. 4A).  Flow cytometry showed fewer pro- and pre-B cells with surface 
expression of CD19 (7.2% vs 68.4%) or pre-BCR (0.1% vs. 0.3%) in mb1-fl/fl mouse 
BM compared to controls (Fig. 4, B and C).  Interestingly, flt3 gene expression was 
highly increased in c-Myc deficient pre-B (36-fold) compared to control cells, higher 
than described for pax-5-/+ B cells (14).  This probably reflects the need for additional 
factors under the control of c-Myc, other than Pax-5, required for normal regulation of 
flt3 promoter.  In contrast, cd19 promoter, under the tight control of Pax-5 is more 
sensitive to small variations of gene expression of this transcription factor (Fig. 4C).  
Consistent with these results, gene expression of Pax-5 target genes blnk (12), cd79a, 
cd79b, n-myc (41) was reduced in B220+IgM- cells (pro- and pre-B) from mb1-fl/fl mice 
(supplemental Fig. S4A).  Similarly, pro- and pre-B cells from gfp-mx-fl/fl mice showed 
reduced cd79b, cd79a and pax-5 expression (supplemental Fig. S4B). To test whether 
decreased pax-5 expression promoted transdifferentiation of c-Myc-deficient B cells 
into T cells (42), we cultured pro- and pre- B cells with the OP9-DL-1 cell line (43).  
Genomic PCR analysis indicated no TCR recombination in cultures of c-Myc-deficient 
B cells from gfp-mb1-fl/fl mouse BM (supplemental Fig. S5). 
 
EBF-1 is a transcriptional target of c-Myc 
ebf-1 gene expression is controlled by two promoters, α  and β , which are differentially 
regulated in B cells (44).  We identified two conserved c-Myc-binding sites (E-boxes) in 
human and mouse, upstream of or within the ebf-1 α-promoter.  In reporter assays on 
293T fibroblasts, a 1.5 Kb genomic region containing the ebf-1 β-promoter did not 
activate the luciferase gene in a c-Myc dose-dependent manner (supplemental Fig. S5, 
A and B).  Mutant deletion analysis identified a 0.9 Kb region of the ebf-1 α-promoter 
that activated the luciferase reporter in a c-Myc dose-dependent manner in fibroblasts 
(2.5-fold) and in the L1-2 B cell line (2-fold) (Fig. 5, A-C). Luciferase assays showed 
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that site-directed mutagenesis of the E-box5 (EB∆5), located 200 bp upstream of the 
transcription start site, completely abolished basal promoter activity and c-Myc-
dependent ebf-1 transactivation in both cell lines (Fig. 5, A-C).  c-Myc-dependent 
transactivation was not observed with genomic regions containing the pax-5 or tcfe2a 
promoters (supplemental Fig. S5, C and D). 
To determine whether c-Myc binds to a genomic region containing E-box5, we 
performed chromatin immunoprecipitation assays (ChIP) in L1-2 cells (45).  Using 
specific primers that flank E-box5, we observed a 10-fold enrichment by PCR of the 
DNA fragments immunoprecipitated with a c-Myc-specific antibody compared to pre-
immune serum (Fig. 5D).  We used EMSA assays to determine whether c-Myc bound 
specifically to this E-box5; c-Myc bound to oligonucleotides containing E-box5 from the 
ebf-1 locus. Mutated E-box5 or E-box4 did not compete for c-Myc binding with 
unmutated E-box5, as determined using anti-c-Myc antibody (Fig. 5E, top).  c-Myc 
binds to an E-box located in a region 5´ of the dhfr gene (46).  We observed that E-
box5 from ebf-1 competed for c-Myc binding with oligonucleotides containing dhfr E-
box. Mutated ebf-1 E-box5 or E-box4 did not compete with the dhfr E-box (Fig. 5E, 
bottom).  Together these data show that c-Myc directly regulates ebf-1 transcription by 
binding to the E-box5 in the ebf-1 α-promoter. 
 
In vitro rescue of B cell differentiation in c-Myc-deficient B lymphocytes  
To determine whether restoration of EBF-1 expression in c-Myc-deficient B 
lymphocytes promotes B cell differentiation, we cultured BM progenitors (Lin-) from 
mb1-fl/fl and mb1-fl/+ control mice and infected them with a retrovirus expressing EBF-
1-GFP or a GFP-control vector.  After six days in culture with IL-7, the BM progenitors 
from mb1-fl/fl mice infected with EBF1-expressing retrovirus generated c-Myc-deficient 
B220+CD19+GFP+ cells (Fig. 6A).  We did not observe surface expression of IgM in c-
Myc-deficient B220+CD19+GFP+ infected with EBF1-expressing retrovirus (not shown).  
To see whether EBF-1-induced differentiation in c-Myc deficient B cells affected V(D)J 
recombination we performed genomic PCR on these cells.  Genomic DNA was 
isolated from either sorted B220+CD19+GFP+ or B220+CD19-GFP+ cells infected with 
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either EBF-1 or GFP control retrovirus from mb1-fl/fl and mb1-fl/+ control mice.  
B220+CD19+GFP+ population was not generated from mb1-fl/fl mouse when infected 
with control retrovirus (Fig. 6A).  We observed an increase in Dh-to-Jh rearrangements 
in EBF-1-infected B220+CD19+GFP+cells compared to B220+CD19-GFP+ infected with 
control retrovirus (Fig. 6B).  Vh- to DhJh rearrangements were hardly detected in both 
populations infected with either retrovirus (Fig. 6B).  We concluded from these 
experiments that EBF-1 promoted B cell differentiation in c-Myc deficient B cells by 
inducing CD19 expression and contributing to DJ rearrangements.  
To see whether rescue by EBF-1 of B lymphocyte differentiation in c-Myc deficient B 
cells affected cell proliferation B220+CD19+ infected cells were stained with propidium 
iodide from mb1-fl/fl and mb1-fl/+ control mice.  We observed that expression of EBF-1 
did not restore the normal capacity to proliferate (39.4% vs 11.8 %) in c-Myc deficient 
B cells (Fig. 6C). 
Pax-5 is transcriptionally regulated by EBF-1 and activates B cell-specific genes such 
as cd19 (11, 44), conferring B cell identity on these cells (7).  To test whether ectopic 
expression of EBF-1 was accompanied by activation of pax-5 expression, we 
performed qPCR in sorted B220+CD19+GFP+ cells.  c-Myc-deficient B220+CD19+GFP+ 
cells expressed higher pax-5 levels than did control retrovirus-infected c-Myc-deficient 
B220+CD19-GFP+ cells from the same mice.  We did not observe changes in gene 
expression in n-myc and tcfe2a (Fig. 6D).  We concluded that ectopic expression EBF-
1 promotes B cell differentiation by inducing CD19 expression in c-Myc deficient B 
lymphocytes. 
To test whether Pax-5 expression alone contributed to the rescue of B lymphocyte 
differentiation in c-Myc-deficient B lymphocytes, we bred mx-fl/fl with ikneo/+ mice (30) 
to generate ikneo/+;c-mycfl/fl;mx-cre+ mice (ik-mx-fl/fl).  ikneo/+ mice express pax-5 from 
the endogenous ikaros promoter upon deletion by the Cre recombinase of a stop 
codon flanked by loxp sites.  In ik-mx-fl/fl mice, pIpC injection leads to Cre 
recombinase expression and deletion of c-myc and activation of pax-5 expression from 
the endogenous ikaros promoter.  Attempts to rescue B cell differentiation by 
expressing pax-5 in ik-mb-1-fl/fl mice were unsuccessful probably due to the low levels 
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of pax-5 expression in these mice (supplemental Fig. S7, A-C and Fig. S8).  Flow 
cytometry analysis of B cell populations in the BM of pIpC-injected ik-mx-fl/fl mice 
showed no significant differences in the number of c-Myc deficient pro- and pre-B cells 
and a five-fold increase in immature B lymphocytes (0.5 x 106 vs 0.1 x 106) compared 
to mx-fl/fl mice (Fig. 7, A, B and C).  We also observed an increase in the number of 
CD19-expressing pro- and pre-B cells in ik-mx-fl/fl mice (73.1% vs 42.5%) (Fig. 7A).  
We concluded that Pax-5 contributed to promote B cell differentiation in c-Myc deficient 
B lymphocytes. 
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DISCUSSION 
Since the discovery of c-Myc, an extensive scientific literature has addressed its 
function in various experimental settings (16).  The prominent role of c-Myc in the cell 
cycle and in apoptosis has been the focus of many reports using various cell types, 
including B lymphocytes.  The specific function of this gene in B lymphocyte 
differentiation nonetheless remains poorly understood, probably due to the lack of 
mouse models suitable for its study.  Here we addressed the role of c-Myc in B cell 
differentiation in vivo, and found that c-Myc regulates this process in part by conferring 
identity to early B lymphocyte precursors. 
The generation of mb1-fl/fl and mx-fl/fl mouse models allowed us to define the 
requirements for c-Myc in B lymphocytes at distinct developmental stages.  Conditional 
inactivation of c-myc in mb1-fl/fl mice showed that this gene is required at least from 
pre-B to immature B cell stages; we observed a reduction in pre-B cells and increased 
apoptosis in these cells (Fig. 1 and 2).  Fewer pro-B cells are affected than pre-B cells, 
probably due to the time at which c-myc deletion occurs in these mice.  The reduced 
number of cells that express GFP in gfp-mb1-fl/fl mouse BM probably reflects 
increased apoptosis in c-Myc-deficient B lymphocytes as well as the accessibility of 
both loci to Cre recombinase (47).  A similar block during transition from the pro-B cell 
to the pre-B cell has been described for the mb1-cre-mediated deletion of c-myb, a 
known gene regulating c-myc (48). Our results are in agreement and provide evidence 
of a more prominent role of c-Myc in collaboration with c-Myb in the regulation of these 
processes via EBF-1. 
The increased apoptosis observed at all developmental stages except in mature B 
cells (21), and the inability of mx-fl/fl (34) and mb1-fl/fl mice to generate B220+IgM+ 
cells in vivo and in vitro (Fig. 2 and supplemental Fig. S3) show the need for c-Myc in 
B cell generation and maintenance during differentiation.  The c-Myc requirement in 
hematopoietic stem cell differentiation (34, 49) probably contributes to the decreased 
number of early B cell precursors in mx-fl/fl mouse BM. 
The role of c-Myc in regulating the G1-S transition of the cell cycle in different cell 
types has been widely studied (19).  At early stages, we observed that B cells lacking 
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c-Myc retain limited proliferative capacity in both mb1-fl/fl and mx-fl/fl mice (Fig. 3, A 
and B).  This ability to proliferate in the absence of c-Myc has been reported for other 
cell types (28, 49, 50).  It is possible that cells are already cycling and that c-myc is 
deleted at stages when the protein is less critical to continue through the cell cycle.  
This might be more relevant at the transition between pro- and pre-B cell stages, when 
extensive expansion occurs (Fig. 3A and B).  Alternatively, this could reflect distinct c-
Myc requirements for cell proliferation, depending on the developmental stage. 
We did not observe c-Myc-dependent transcriptional regulation of tcfe2a or pax-5 
promoters in luciferase reporter assays (supplemental Fig. S6).  The reduced tcfe2a 
gene expression in c-Myc-deficient B lymphocytes nonetheless suggests an indirect 
effect of c-Myc on tcfe2a regulation.  It remains to be determined whether E2A 
expression in c-Myc-deficient B lymphocytes is sufficient to promote B lymphocyte 
differentiation.  We identified ebf1 as a previously unreported c-Myc target gene.  The 
contribution of the ebf1 alpha promoter to the total level ebf1 transcripts is little 
compared to the beta promoter.  However, we believe that this contribution is essential 
at early stages of B cell differentiation due to the complex regulation of ebf-1 
expression as previously described (44).  The activity of the ebf-1 alpha promoter will 
induce expression of pax-5 which in turn will activate the ebf-1 beta promoter. The 
activity of the ebf-1 alpha promoter would induce expression of pax-5 which in 
turn could activate the ebf-1 beta promoter. In c-Myc deficient B cells activation of 
ebf-1 alpha promoter will be compromised, and therefore the total amounts of EBF-1 
mRNA will be dramatically reduced.   
 
  Our results indicate that c-Myc regulates cell proliferation and survival in developing 
B lymphocytes; c-Myc function is thus not restricted to the regulation of ebf-1 
expression in B cell differentiation.   
The observation that c-Myc-deficient pre-B cells undergo a slight reduction but normal 
V(D)J recombination despite decreased tcfe2a (4, 5), ebf-1 (6), and pax-5 (10, 51) 
expression probably reflects cell pool heterogeneity while undergoing c-myc deletion.  
This became more evident when we compared c-Myc-deficient and pax-5-/- B cells.  
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Despite reduced pax-5 expression in c-Myc-deficient B lymphocytes, we observed 
minimal differences in the levels of Vhproximal- and Vhdistal-to-DhJh recombination (10).  
In c-Myc deficient B cells, enforced expression of EBF-1 induces surface expression of 
CD19 and slightly increases the levels of D to J recombination in these cells (Fig. 6B).  
These results might reflect a broad rather than a specific effect of c-Myc deficiency on 
V(D)J machinery (51).  
Unlike pax-5-/- B cells (52), c-Myc-deficient B lymphocytes were unable to differentiate 
to other cell lineages in vivo and in vitro (supplemental Fig. S5 and not shown).  
Although we did not detect B220-GFP+ cells in the thymus, bone marrow or spleen of 
gfp-mb1-fl/fl mice (not shown), it is nonetheless possible that lack of c-Myc confers on 
B lymphocytes the ability to differentiate to other cell lineages.  To test this, the 
increased viability of c-Myc-deficient B cells is essential.  Our attempts to rescue c-
Myc-deficient B lymphocytes from apoptosis by breeding mx-fl/fl with Eµ-bcl-2 
transgenic mice (53) were unsuccessful (not shown). 
The capacity of EBF-1 to induce pax-5 gene expression (41, 54, 55) and to activate 
the B cell transcription program could explain its ability to promote B cell differentiation 
in c-Myc-deficient cells in vitro, despite the large number of genes regulated by c-Myc 
(Fig. 6).  pax-5 expression in ik-mb-1-fl/fl mice nonetheless did not rescue B cell 
differentiation (supplemental Fig. S6).  This might be attributed to the brief time frame 
available for expression of normal Pax-5 levels before cell death following c-Myc 
deletion (supplemental Fig. S7).  In contrast, Pax-5 expression in ik-mx-fl/fl mice 
contributed to a significant increase in the number of c-Myc-deficient immature B cells 
and to cell surface expression of the Pax-5 target CD19 (Fig. 7A).  Pro- and pre-B cell 
number did not increase significantly in ik-mx-fl/fl mice as observed by Souabni et al. 
(30) (Fig. 7B).  In our experimental model, developing B lymphocytes show increase 
cell death upon deletion of c-myc (Fig. 2).  This effect probably makes more difficult to 
increase B cell numbers in our system than in Souabni et al. (30) where Pax-5 is 
overexpressed in a normal background.  Our system does not allow to control when c-
myc deletion and/or pax-5 expression occur with respect to each other.  Moreover, c-
Myc affects B lymphocytes depending on the differentiation stage (21, 22).  Altogether, 
these effects might account for the differences in cell number in immature B 
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lymphocytes in ik-mx-fl/fl mice.  
Our results identified ebf-1 as an unreported c-Myc target gene, and illustrate a novel 
c-Myc function in the regulation of B lymphocyte differentiation.  Through ebf-1 
activation, c-Myc regulates differentiation by promoting B cell identity.  These data 
show that c-Myc not only regulates ebf-1 but also affects multiple biological functions 
during B lymphocyte differentiation such us cell survival or proliferation.  The capacity 
of c-Myc to regulate these functions has been widely studied (16, 19).  
Finally, this study places c-Myc within the context of transcription factors essential for 
B lymphocyte differentiation by linking this transcription factor to the EBF-1-Pax-5 
pathway.  Based on these data, a model emerges for transcriptional regulation of B 
lymphocyte differentiation in which c-Myc acts by regulating B or T cell-specific 
transcription factors.  This model postulates a requirement for one or more additional 
factor(s) to allow c-Myc to discriminate between B and T cell lineages.  
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FIGURE	  LEGENDS	  
FIGURE 1. c-Myc is necessary for B lymphocyte differentiation.  A, B, B lymphocyte 
differentiation is blocked at the pre-B cell stage in mb1-fl/fl mouse BM.  Single-cell 
suspensions were prepared from mb1-fl/fl and mb1-fl/+ mice, stained and analyzed by flow 
cytometry (see methods).  Cells were defined as (Ly6c-NK1.1-DX5-B220+c-Kit+IgM-) pro-B 
and (Ly6c-NK1.1-DX5-B220+CD25+IgM-) pre-B cells.  C, Flow cytometry analysis of Hardy 
Fractions in BM of mb1-fl/fl and mb1-fl/+ control mice.  B220+CD43+ and B220+CD43- gates 
and NK and dendritic cells discrimination were as 1A.  D, E, Absolute numbers of B 
lymphocytes in mb1-fl/fl and control mouse BM (n =7) and spleen (n=3).  F, Flow cytometry 
analysis of B lymphocytes from pIpC-injected mx-fl/fl and fl/fl mouse BM. mb1-fl/+ = c-
mycfl/+;mb-1cre/+.  G, Flow cytometry analysis of Hardy Fractions in BM of mx-fl/fl mice.  Data 
represent one of ≥3 independent experiments. p values are ***p<0.001, **p<0.01, *p<0.05. 
 
FIGURE 2. Increased apoptosis in developing c-Myc deficient B lymphocytes.  A, Apoptosis 
in pro- and pre-B cells in mb1-fl/fl mice.  Cells were antibody- and annexin-V-stained and 
gated as in Fig. 1B.  B, Pro-, pre- and immature B lymphocytes die by apoptosis following c-
myc deletion in mx-fl/fl mice.  BM cells were stained as in Fig. 1F, and B cell populations 
analyzed by flow cytometry using gates as in Fig. 1 F. Experiments representative of three 
independent experiments. 
 
FIGURE 3.  Cell proliferation and V(D)J recombination of c-Myc-deficient B lymphocytes.  
A, Decreased proliferation of sorted pro-B and pre-B cells from mb1-fl/fl.  Cells were stained as 
in 1B and BrdU incorporation was measured by flow cytometry in (Ly6c-NK1.1-DX5-B220+c-
Kit+IgM-) pro-B and (Ly6c-NK1.1-DX5-B220+CD25+IgM-) pre-B cells in the BM.  B, Pro- and 
pre-B cells from mx-fl/fl mouse BM.  Mice were BrdU-injected 2 h before analysis; n=3 for 
mb1-fl/fl and n=5 for mx-fl/fl. C, V(D)J recombination analysis in sorted pro-B and pre-B cells 
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from mb1-fl/fl or control mice. Genomic PCR from sorted BM pro- and pre-B cells defined as 
in 1B was performed using specific primers to detect D to JH or VH to DJH rearrangements (see 
Methods).  Three mice of each genotype were analyzed; DNA from rag-1-/- was included as 
negative control.  D, VDJ rearrangement levels were quantified by measuring the fluorescent 
intensity of the amplified PCR fragments in the agarose gel using ImageJ software. Fold IntDen 
indicates the integrated intensity average ratio of mb1-fl/fl vs control samples, including the 
three 5-fold dilutions of three different mice from each genotype, after GAPDH normalization.  
NS, not significant. p values are ***p<0.001, **p<0.01, *p<0.05 
 
FIGURE 4. Gene expression in c-Myc deficient B lymphocytes.  A, qPCR of sorted  pro-B and 
pre-B cells from mb1-fl/fl and mb1-fl/+ control mouse BM.  Each panel shows an independent 
experiment  (mean ± SD for 3 mutant and 3 control mice); numbers indicate the x-fold change 
(2-∆Ct).  B, C, Flow cytometry analysis of pre-BCR and CD19 surface expression on mb1-fl/fl 
and mb1-fl/+ mouse BM B lymphocytes.  c-myc transgenic (Eµ-c-myc) and rag-1-/- mice were 
included for comparison.  Experiment representative of at least three independent experiments. 
 
FIGURE 5. c-Myc transcriptionally regulates ebf-1.  A, Luciferase reporter constructs.  B, C, 
c-Myc dose-dependent activation of ebf-1 in HEK293T and L1-2 cells (B cells) in transient 
transfection assays.  Luciferase activity was normalized with Renilla activity (relative 
luciferase units, RLU).  Mean ± SD for three replicates in one representative experiment.  p 
values are ***p<0.001 and *p<0.05. D, ChIP assays in L1-2 B cells. Immunoprecipitation was 
performed with anti-c-Myc antibody (N262) or pre-immune serum (control).  Data show the 
mean of three independent experiments. *p<0.05.  E, EMSA assays. In vitro-translated c-Myc 
and Max proteins were incubated with oligonucleotides containing E-box5 from ebf-1 (top) or 
E-box from dhfr (bottom) and the indicated competitor oligonucleotides. Lane 1, negative 
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control without c-Myc and Max. Lane 2, no competitor.  Lane 9, negative control with anti-c-
Myb antibody. Arrow indicates the shift of c-Myc-Max oligonucleotide complexes. All 
experiments are representative of at least three independent assays. 
 
FIGURE 6. Ectopic expression of EBF-1 rescues B lymphocyte differentiation in c-Myc-
deficient B lymphocytes.  A, Lin- cells from mb1-fl/fl and mb1-fl/+ mouse BM were isolated 
and infected with ebf-1-gfp-expressing or gfp retrovirus.  Cells were harvested after 6 days, 
antibody-stained and analyzed by flow cytometry.  Experiment representative of at least three 
independent assays.  B, V(D)J recombination in c-Myc deficient B lymphocytes ectopically 
expressing EBF-1.  Genomic PCR was performed on DNA from sorted B220+CD19+GFP+ or 
B220+CD19-GFP+ cells infected with EBF-1 or GFP control retrovirus from a pool of four 
mb1-fl/fl and three mb1-fl/+ control mice.  C, Cell cycle analysis of sorted B220+CD19+GFP+ 
infected with ebf-1-expressing retrovirus as in 6A.  Cells were sorted and stained with 
propidium iodide.  Experiment representative of two independent experiments.  D, Gene 
expression of pax-5, ebf-1, tcfe2a and n-myc in ebf-1-infected cells.  Cells were infected as in 
6A, sorted and analyzed by qPCR.  A pool of three mice of each genotype was used. 
 
FIGURE 7. Pax-5 expression contributes to differentiation of c-Myc-deficient B lymphocytes.  
A, Flow cytometry analysis of ik-mx-fl/fl and control mouse BM.  B, Absolute numbers of B 
cell subpopulations in BM of mice in A.  **p<0.01, ik-mx-fl/fl, n = 5; fl/fl, n = 6; mx-fl/fl, n = 4. 
C, c-myc deletion in sorted populations from mice of the indicated genotypes.  Experiment 
representative of two independent experiments. 
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